doxazosin has been researched along with prazosin in 337 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 130 (38.58) | 18.7374 |
| 1990's | 120 (35.61) | 18.2507 |
| 2000's | 54 (16.02) | 29.6817 |
| 2010's | 28 (8.31) | 24.3611 |
| 2020's | 5 (1.48) | 2.80 |
| Authors | Studies |
|---|---|
| Campbell, SF; Davey, MJ; Hardstone, JD; Lewis, BN; Palmer, MJ | 1 |
| Bondinell, WE; Hieble, JP; Ruffolo, RR | 1 |
| Ballard, S; Blagg, J; Fox, D; Kenny, B | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Pedretti, A; Testa, B; Villa, L; Vistoli, G | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Kinsella, GK; Rodriguez, F; Rozas, I; Watson, GW | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ang, KK; Arkin, MR; Chen, S; Doyle, PS; Engel, JC; McKerrow, JH | 1 |
| Sen, S; Sinha, N | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cilia, A; Maestri, V; Minarini, A; Naldi, M; Nicolini, B; Poggesi, E; Pruccoli, L; Rosini, M; Simoni, E; Tarozzi, A | 1 |
| Bobba, V; Geldenhuys, WJ; Idippily, N; Petty, A; Su, B; Wang, B; Zhong, B | 1 |
| Heinzl, S | 1 |
| Marwood, JF; Stokes, GS; Tierney, G | 1 |
| Johnston, H; Marwood, JF; Monaghan, JC; Okoro, EO; Stokes, GS | 1 |
| Feurle, GE | 1 |
| Charuel, C; Comby, P; Monro, AM | 1 |
| Babamoto, KS; Hirokawa, WT | 1 |
| Agabiti-Rosei, E; Beschi, M; Calebich, S; Castellano, M; Muiesan, G; Muiesan, ML; Rizzoni, D; Zulli, R | 1 |
| Foxall, TL; Nicolosi, RJ; Shwaery, GT; Stucchi, AF; Wong, SS | 1 |
| Leren, P | 2 |
| Draaijer, P; Gladziwa, U; Kooman, JP; Leunissen, KM; Peltenburg, HG; Struyker-Boudier, HA; van Bortel, LM; van Hooff, JP; Wijnen, JA | 1 |
| Jansen van't Land, C; van der Laan, JW | 1 |
| Donnelly, R; Elliott, HL; Howie, CA; Meredith, PA; Reid, JL | 1 |
| Kelly, JG; Reynolds, GW; Richmond, A; Silke, B; Taylor, SH; Verma, SP | 1 |
| Bodansky, HJ | 1 |
| Daly, L; Devlin, JG; McLaughlin, B | 1 |
| Bak, M; Christensen, S; Lomholt, N; Petersen, JS; Shalmi, M | 1 |
| de Planque, BA | 1 |
| Barlage, U; Englert, RG | 1 |
| Chakko, S; DiBianco, R; Emmanuel, G; Marlon, A; Parker, JO; Singh, JB; Tanser, PH | 1 |
| Kaplan, NM; Khoury, AF | 1 |
| Marwood, J; Stokes, G; Tierney, G | 3 |
| Abildgaard, U; Christensen, S; Petersen, JS; Shalmi, M | 1 |
| Colagrande, F; Jackman, GP; Louis, WJ | 1 |
| McInnes, GT | 1 |
| Gagało, I; Szreder, Z | 1 |
| Elsegood, CL; Mackintosh, VS; Redgrave, TG | 1 |
| Branzi, A; Galiè, N; Limonetti, P; Magnani, B; Passarelli, P | 1 |
| Durham, SK; Kowala, MC; Nicolosi, RJ; Nunnari, JJ | 1 |
| Brown, MJ; Dickerson, JE | 1 |
| Jarry, H; Leonhardt, S; Wuttke, W | 1 |
| Donnelly, R; Elliott, HL; Howie, CA; Reid, JL; Sumner, DJ | 1 |
| Birkenhäger, JC; Jansen, H | 1 |
| Grong, K; Hexeberg, E; Lekven, J; Myking, OL; Olweus, J; Westby, J | 1 |
| Pool, JL | 2 |
| Fauchald, P; Holme, I; Rugstad, HE; Stokke, HP | 1 |
| Langdon, CG | 1 |
| Naber, FB | 1 |
| Daae, L; Talseth, T; Westlie, L | 2 |
| Taylor, SH | 4 |
| Wessels, F | 1 |
| Fukiyama, K; Iimura, O; Ijichi, H; Inagaki, Y; Ishii, M; Kaneko, Y; Omae, T; Yagi, S; Yamada, K; Yoshinaga, K | 1 |
| Maslowski, AH | 1 |
| Fonseca, R; Marshall, D; Silva, H | 1 |
| Bonnet, G | 1 |
| Harmse, DP | 1 |
| Manos, J | 1 |
| Corral, JL; López, NC; Pecorelli, A; Rincón, LA; Terán, VD | 1 |
| Fonseca, R; López, B; Lugo de Franco, V; Medina, O; Monsalve, P; Ostojich, K; Pérez Acuña, F; Torres, N; Vera, O | 1 |
| Catalano, M; Libretti, A | 1 |
| Miura, Y; Watanabe, M; Yoshinaga, K | 1 |
| Armas de Hernandez, MJ; Armas Padilla, MC; Barragan, O; Boada Boada, JJ; Carvajal, AR; Guerrero Pajuelo, J; Hernandez Hernandez, R; Roa, E | 1 |
| Armas de Hernandez, MJ; Armas Padilla, MC; Barragan, O; Boada Boada, JJ; Carvajal, AR; Guerrero Pajuelo, JR; Hernandez Hernandez, R | 1 |
| Colina-Chourio, JA; Godoy-Godoy, N; Oliveros-Palacios, MC | 1 |
| Crepaldi, G; D'Angelo, A; Nosadini, R | 1 |
| Feher, MD | 1 |
| Lehtonen, A | 1 |
| Brusletto, B; Daae, LN; Holme, I; Kierulf, P; Syvertsen, JO; Westheim, A | 2 |
| Boman, K; Jansson, JH; Johansson, B; Nilsson, TK | 1 |
| Brinchmann-Hansen, O; Myhre, K | 1 |
| Donnelly, R; Elliott, HL; Meredith, PA; Reid, JL | 2 |
| Lund-Johansen, P; Omvik, P | 1 |
| Baumann, M; Lepor, H; Shapiro, E | 1 |
| Lindgren, B | 1 |
| Birkeland, S; Grong, K; Kvitting, P; Lekven, J; Westby, J | 2 |
| Lenz, ML; Pool, JL; Taylor, AA | 1 |
| Maclean, D; McDevitt, DG | 1 |
| Elkeles, RS; Feher, MD; Gelding, S; Henderson, AD; Poulter, C; Richmond, W; Sever, PS; Wadsworth, J | 1 |
| Bornmyr, S; De Pedis, G; Hulthén, UL; Lecerof, H; Lilja, B | 1 |
| Groppelli, A; Mancia, G; Omboni, S; Parati, G | 1 |
| Daae, LN; Talseth, T; Westlie, L | 1 |
| Dewhurst, AG; Honeywell, R; Oliver, RM; Renwick, AG; Upward, JW; Waller, DG | 1 |
| Aursnes, I | 1 |
| Christensen, CC; Dathan, R; Dean, S; Searle, M; Westheim, A | 1 |
| Jansen, H | 1 |
| Brown, MJ | 1 |
| Oliver, RM; Waller, DG | 1 |
| Anderton, JL; Notghi, A | 1 |
| Amery, A; Fagard, R; Lijnen, P; Staessen, J | 2 |
| Buzzaccarini, F; Casolino, P; Giusto, M; Mozzato, MG; Pessina, AC; Rubino, N; Semplicini, A; Serena, L; Valle, R | 1 |
| Calvete, J; Hayes, R; Sever, PS; Thom, S | 1 |
| Jie, K; Timmermans, PB; van Brummelen, P; van Zwieten, PA; Vermey, P | 4 |
| Kaneko, Y; Miyajima, E; Miyakawa, T; Shionoiri, H; Takagi, N; Umemura, S; Yasuda, G; Yoshimura, H | 1 |
| Baggen, RG; Jansen, H | 1 |
| Chichester, CO; Rodgers, RL | 1 |
| Swindell, AC; Woodside, WF | 1 |
| Miller, NE; Nanjee, MN | 1 |
| Hughes, A; Inkpen, P; Sever, P | 1 |
| Anavekar, SN; Conway, EL; Drummer, OH; Howes, LG; Jarrott, B; Louis, WJ; McNeil, JJ; Workman, B | 1 |
| D'Eletto, RD; Javitt, NB | 1 |
| Hoover, KW; Krupp, MN; Valentine, JJ | 1 |
| Swindell, AC; Valentine, JJ | 2 |
| Karge, WH; Kowala, MC; Nicolosi, RJ; Weiner, EJ | 1 |
| Ontko, JA; Woodside, WF | 2 |
| Kowala, MC; Nicolosi, RJ | 1 |
| Baggen, MG; Birkenhäger, JC; Jansen, H; Lammers, R | 1 |
| Dzau, VJ | 1 |
| Amery, A; Fagard, R; Lijnen, P; Lissens, W; Staessen, J | 1 |
| Bevegård, S; Ekenvall, L; Etzell, BM; Lindblad, LE | 1 |
| Bautovich, GJ; Fletcher, PJ; Gillin, AG; Horvath, JS; Hutton, BF; Tiller, DJ | 1 |
| Conway, EL; Drummer, OH; Howes, LG; Louis, WJ; McNeil, JJ; Meng, L; Raymond, K | 1 |
| Ames, RP; Chrysant, SG; Gonzalez, F; Schnaper, HW; Spann, S; Velasquez, MT | 1 |
| Ose, L | 1 |
| Ganzinger, U | 1 |
| Bruschke, AV; Mauve, I; Mohanlal, RW; van der Laarse, A; van der Valk, L | 1 |
| Hughes, AD; Martin, GN; Mulvany, MJ; Nielsen, H; Sever, PS; Thom, SM | 1 |
| Baggen, MG; Birkenhäger, JC; Jansen, H; Lammers, R; Penders, JM | 1 |
| Ames, RP; Kiyasu, JY | 1 |
| Davey, MJ | 1 |
| Nelson, EB; Pool, JL; Taylor, AA | 1 |
| Biernacki, W; Flenley, DC | 1 |
| Buzzaccarini, F; Casiglia, E; Casolino, P; Mozzato, MG; Pessina, AC; Rubino, N; Semplicini, A; Serena, L; Valle, R | 1 |
| Grimm, RH | 1 |
| Calvete, J; Hayes, R; Martin, G; Sever, P; Thom, S | 1 |
| Alabaster, VA; Solca, AM | 1 |
| Leren, TP | 1 |
| Hamilton, CA; Reid, JL; Vincent, J | 1 |
| Gaba, DM; Hayward, E; Maze, M | 1 |
| Elliott, HL; Meredith, PA; Reid, JL; Vincent, J | 3 |
| Alabaster, VA; Davey, MJ | 1 |
| Reid, JL; Vincent, J | 1 |
| Davey, M | 1 |
| Hayduk, K | 1 |
| Rosenthal, J | 3 |
| Cox, DA; Frick, MH; Himanen, P; Huttunen, M; Pitkäjärvi, T; Pörsti, P; Pöyhönen, L; Pyykönen, ML; Reinikainen, P; Salmela, P | 1 |
| Madsbu, HP; Torvik, D | 2 |
| Badskjaer, J; Faergeman, O; Jensen, H; Krusell, LR; Ott, P; Storm, TL | 1 |
| Elliott, HL; Meredith, PA; Reid, JL | 1 |
| Wilner, KD; Ziegler, MG | 1 |
| Black, H; Nash, DT; Reeves, RL; Schonfeld, G; Weidler, DJ | 1 |
| Hayduk, K; Schneider, HT | 1 |
| Claessens, J; Nelemans, F; Riesen, W; Streulens, Y; Trost, BN; Weidmann, P | 1 |
| Birkenhäger, WH; de Bos, R; de Leeuw, PW; van Es, PN | 3 |
| Elliott, HL; Kelman, AW; Meredith, PA; Reid, JL; Vincent, J | 1 |
| Brogden, RN; Young, RA | 1 |
| Ekenvall, L; Etzell, BM; Lindblad, LE; Norbeck, O | 1 |
| van den Hogen, AL | 1 |
| Guevara, J; Silva, H; Soltero, I; Velasco, M | 1 |
| Bartels, AC; de Vries, PM; Donker, AJ; Fillastre, JP; Oe, LP; Réveillaud, RJ; van Bronswÿk, H; Zech, P | 1 |
| Al Awady, M; Castrignano, R; Crepaldi, G; D'Angelo, A; Pati, T; Tronca, R | 1 |
| Miura, Y; Yoshinaga, K | 1 |
| Daae, L; Talseth, T; Vatle, S; Westlie, L | 1 |
| Guerrasio, E; Mazzola, C | 1 |
| Fioravanti, G; Giorgi, G; Legramante, A; Legramante, JM; Paies, G | 1 |
| Berger, J; Blumrich, W; Bouzo, H; Brandl, K; Braun, S; Laukaitis, A; Müller, G; Nechwatal, W; Ryba, W; Schreiegg, J | 1 |
| Lindner, UK; Stafunsky, M; von Manteuffel, GE | 1 |
| Lee, PS; Sharma, SK; Taylor, SH | 1 |
| Englert, RG; Mauersberger, H | 1 |
| Hansson, L | 1 |
| Birkenhäger, WH; de Leeuw, PW | 1 |
| Berg, K; Leren, TP | 1 |
| Cowlishaw, MG; Sharman, JR | 1 |
| Cussans, NJ; Faulkner, JK; Kaye, B; Reid, JL; Stopher, DA | 1 |
| Haugland, H; Lund-Johansen, P; Omvik, P | 1 |
| Frick, MH; Halttunen, P; Himanen, P; Huttunen, M; Pitkäjärvi, T; Pörsti, P; Pöyhönen, L; Pyykönen, ML; Reinikainen, P; Salmela, P | 1 |
| Baez, MA; Garg, DC; Jallad, NS; Weidler, DJ | 1 |
| Himanen, P; Lehtonen, A; Marniemi, J; Niittymäki, K; Saraste, M | 1 |
| Cox, DA; Leader, JP; Milson, JA; Singleton, W | 1 |
| Bailey, RR; Begg, EJ; Carlson, RV; Cowlishaw, MG; Sharman, JR | 1 |
| Bailey, RR; Nairn, PL; Walker, RJ | 1 |
| Caplan, N; Cubeddu, LX; Ferry, D; Fuenmayor, N | 1 |
| Faulkner, JK; Himanen, P; Karjalainen, U; Saraste, M | 1 |
| Daae, L; Hjermann, I; Hjortdahl, P; Holme, I; von Krogh, H | 1 |
| Butty, J; Gordon, D; Whitworth, JA | 1 |
| Nechwatal, W | 1 |
| Hosie, J; Scott, MG; Scott, PJ | 1 |
| Bloomfield, R; Cubeddu, LX; Halperin, A; Klotman, PE; Nelson, EB; Pickering, BI; Pool, JL; Wombolt, DG | 1 |
| Krusell, LR; Ott, P; Storm, T | 1 |
| Jackson, G; Lorimer, AR; Pringle, S; Smyth, P | 1 |
| Conrad, KA; Fagan, TC; Falkner, FC; Lazar, JD; Lee, S; Mackie, MJ; Mayshar, PV; Souhrada, JF | 1 |
| Fouda, HG; Schneider, RP; Twomey, TM | 1 |
| Campbell, SF; Davey, MJ | 1 |
| Ramage, AG | 1 |
| Ali, FK; Kwa, HY; Timmermans, PB; van Zwieten, PA | 1 |
| Moulds, RF; Stevens, MJ | 1 |
| Elliott, HL; McLean, K; Meredith, PA; Reid, JL; Sumner, DJ | 1 |
| Birkenhäger, WH; de Leeuw, PW; Ligthart, JJ; Smout, AJ | 1 |
| Downing, OA; Wilson, KA; Wilson, VG | 1 |
| Hernandez, J; Prichard, BN; Saxton, CA; Singleton, W | 1 |
| Elliott, HL; Reid, JL; Sumner, DJ | 1 |
| Ali, FK; Kossen, SP; Timmermans, PB; Van Zwieten, PA | 1 |
| Brunton, J; Meredith, P; Rubin, PC | 1 |
| Stockamp, K | 1 |
| Chalmers, DH; Kenny, BA; Naylor, AM; Philpott, PC | 1 |
| Dutkiewicz, S; Witeska, A | 1 |
| Carter, AJ; Greengrass, PM; Kenny, BA; Naylor, AM; Read, AM; Wyllie, MG | 1 |
| Kaplan, SA; Olsson, CA; Soldo, KA | 1 |
| Dutkiewicz, S; Stepień, K; Witeska, A | 1 |
| Chapple, CR | 2 |
| Angeli-Greaves, M; Armas Padilla, MC; Armas-Hernández, MJ; Carvajal, AR; Guerrero Pajuelo, J; Hernández Hernández, R | 1 |
| Ramage, AG; Wyllie, MG | 1 |
| Mikami, H | 1 |
| Chalmers, DH; Kenny, BA; Miller, AM; Naylor, AM; O'Connell, J; Williamson, IJ | 1 |
| Beevers, DG; Marshall, HJ | 1 |
| Hatano, A; Lepor, H; Tang, R; Walden, PD | 1 |
| Crucianelli, M; Giardinà, D; Marucci, G; Massi, M; Melchiorre, C; Polidori, C; Pompei, P | 1 |
| Frankel, S | 1 |
| Brune, ME; Buckner, SA; Hancock, AA; Ireland, LM; Katwala, SP; Kerwin, JF; Milicic, I | 1 |
| Vatz, KA | 1 |
| Andersson, KE; Lepor, H; Wyllie, MG | 1 |
| Fernández Arjona, M; Fernández Borrell, A; Gómez Sancha, F; Mínguez Martínez, R; Peinado Ibarra, F; Pereira Sanz, I | 1 |
| Ikeguchi, E; Kaplan, SA; Santarosa, RP; Te, AE | 1 |
| Beduschi, MC; Beduschi, R; Oesterling, JE | 1 |
| Benos, DJ; Bradford, AL; Bubien, JK; Cornwell, T; DuVall, MD; Fuller, CM | 1 |
| Chung, M; Hilbert, J; Lawrence, V; Phillips, K; Vashi, V | 1 |
| Kim, SC; Lee, MY; Lim, SW; Seo, KK | 1 |
| Borkowski, A; Chon, JK; Isaacs, JT; Jacobs, SC; Kyprianou, N; Partin, AW | 1 |
| Djavan, B; Marberger, M | 1 |
| Hoffman, RM; Jansen, DJ; Resch, ND | 1 |
| Eglen, RM; MacLennan, SJ; Martin, GR; Martin, RS; Reynen, PH | 1 |
| Eglen, RM; MacLennan, SJ; Martin, GR; Reynen, PH | 1 |
| Clifford, GM; Farmer, RD | 1 |
| Benning, CM; Kyprianou, N | 2 |
| Benning, CM; Chon, J; Kyprianou, N | 1 |
| Caprino, L | 1 |
| Blanchard, K; Hananel, A; Rutchik, S; Sullivan, J | 1 |
| Cotecchia, S; Goepel, M; Hein, P; Michel, MC | 1 |
| Altenbach, RJ; Bai, H; Basha, FZ; Brune, ME; Buckner, SA; Carroll, WA; Drizin, I; Hancock, AA; Kerwin, JF; Lebold, SA; Lee, E; Meyer, MD; Pratt, JK; Sippy, KB; Tietje, K; Wendt, MD | 1 |
| Chao, J; Chrischilles, E; Gilden, D; Kreder, KJ; Rubenstein, L; Shah, H | 1 |
| Akduman, B; Crawford, ED | 1 |
| Jacobs, SC; Kyprianou, N | 1 |
| Ambrosioni, E | 1 |
| Butler, WM; Galbreath, RW; Lief, JH; Merrick, GS; Wallner, KE | 1 |
| Baykara, M; Ciftcioglu, MA; Emreoglu, I; Erdoğru, T; Gulkesen, KH; Koksal, T; Ozbilim, G; Usta, MF | 1 |
| Alcaide, C; González-Juanatey, JR; Iglesias, MJ; Lago, F; Piñeiro, R | 1 |
| Keledjian, K; Kyprianou, N | 1 |
| Niu, CQ; Ren, LM | 1 |
| Kyprianou, N | 1 |
| Gonzalez, CM; McVary, KT | 1 |
| Romics, I | 1 |
| Bakshi, M; Ojha, T; Singh, S | 1 |
| Barqawi, A; Crawford, ED; Gamito, E; O'Donnell, C | 1 |
| Kyprianou, N; Tahmatzopoulos, A | 1 |
| Brown, GA; Sussman, DO | 1 |
| Ficker, EK; Hammerling, BC; Karle, CA; Katus, HA; Kiehn, J; Kuryshev, YA; Schoels, W; Thomas, D; Wimmer, AB; Wu, K | 1 |
| Doggrell, SA | 1 |
| Kyprianou, N; Rowland, RG; Tahmatzopoulos, A | 1 |
| Dincel, C; Samli, MM | 1 |
| Akbay, E; Bozlu, M; Cayan, S; Görür, S; Ulusoy, E | 1 |
| Basar, H; Basar, MM; Batislam, E; Ferhat, M; Tuglu, D; Yilmaz, E | 1 |
| Afshari, NA; Schwinn, DA | 1 |
| Michel, MC; Noguchi, Y; Ohtake, A; Okutsu, H; Sasamata, M; Someya, A; Suzuki, M; Ukai, M; Watanabe, M; Yanai-Inamura, H; Yuyama, H | 1 |
| de la Rosette, JJ; Michel, MC | 1 |
| O'Leary, MP | 1 |
| Akova, YA; Altan-Yaycioglu, R; Ozkardes, H; Tufan, H; Yaycioglu, O | 1 |
| Baron, AT; Becker, A; Conner, W; Durbin, EB; Harris, AM; Kimbler, K; Kyprianou, N; Lane, M; Rowland, RG; Warner, BW; Wilson, JM | 1 |
| Albo, G; Berardi, F; Colabufo, NA; Contino, M; de Rienzo, G; Niso, M; Pagliarulo, A; Pagliarulo, V; Perrone, R | 1 |
| Jin, J; Kong, CZ; Li, NC; Na, YQ; Qiu, SP; Song, YS; Sun, G; Sun, YC; Sun, YH; Wang, XF; Wu, SL; Ye, ZQ | 1 |
| Kitteringham, NR; Macdonald, I; Park, BK; Randle, LE; Sathish, JG; Williams, DP | 1 |
| Mamalis, N | 1 |
| Cheng, XR; Hua, CX; Hua, L; Huang, Y; Kang, J; Li, N; Li, YS; Liu, H; Ming, GH; Pang, HM; Wang, L; Wu, Y; Xu, L; Xu, ZM | 1 |
| Bar-Yosef, Y; Kaver, I; Laufer, M; Mabjeesh, NJ; Matzkin, H; Neulander, EZ | 1 |
| Hoyano, Y; Kobayashi, S; Kusama, H; Maruyama, K; Tomiyama, Y; Yamazaki, Y | 1 |
| Kakumoto, M; Kobayashi, H; Ohnishi, N; Okumura, K; Sakaeda, T; Takara, K; Tanigawara, Y; Yokoyama, T | 1 |
| Acharya, SV; Bandgar, TR; Ganesh, HK; Goerge, J; Menon, PS; Shah, NS | 1 |
| Adomat, H; Elterman, DS; Fleshner, N; Guns, E; Hersey, K; Lawrentschuk, N; Wood, CA | 1 |
| Chen, X; Liu, K; Zhong, D | 1 |
| Chatziralli, IP; Sergentanis, TN | 1 |
| Alan, C; Eren, AE; Ersay, AR; Ertung, Y; Kırılmaz, B; Koçoğlu, H | 1 |
| Krome, S | 1 |
| Du, H; He, L; Ren, J; Wang, S | 1 |
| Casuccio, A; Cillino, G; Cillino, S; Pavone, C; Spitale, E | 1 |
| Gandhi, HP; Giridhar, R; Naik, PP; Yadav, MR | 1 |
| Hill, TM; McEwen, C; Sherman, JJ; Welch, RW | 1 |
| Ahmed, S; El Zohny, SA; Mohamed, NA | 1 |
| Araki, M; Araki, T; Monden, K | 1 |
| Li, AP; Peng, H; Peng, JD; Zhang, J; Zhou, MQ | 1 |
| Barkin, J; Berner, T; Diles, D; Franks, B | 1 |
| Creta, M; Ficarra, V; Fusco, F; Giannarini, G; Longo, N; Mirone, V; Novara, G; Palmieri, A; Verze, P | 1 |
| Anoopkumar-Dukie, S; Chess-Williams, R; Forbes, A; McDermott, C | 1 |
| Coen, K; Funk, D; Lê, AD; Li, Z; Loughlin, A; Tamadon, S | 1 |
| Anoopkumar-Dukie, S; Batty, M; Chess-Williams, R; Christie, D; Forbes, A; McDermott, CM; Pugh, R; Rathinam, I; Simmonds, J; Spencer, B; Walker, E | 1 |
| Belayneh, M; Korownyk, C | 1 |
| Derayea, SM; Hammad, MA; Mohamed, AA; Mohamed, AI; Omar, MA | 1 |
| Du, Q; Kong, DZ; Ren, LM; Zhang, PP | 1 |
| Hammad, MA; Omar, MA; Salman, BI | 1 |
| Hori, Y; Ohyama, K; Sugiura, M | 1 |
| Dahm, P; Hwang, EC; Koziarz, A; Kuntz, GM; Oestreich, MC; Sathianathen, NJ; Scales, CD; Vernooij, RW | 1 |
| Liu, L; Narayanan, NS; Pottegård, A; Simmering, JE; Welsh, MJ | 1 |
| Araújo, AV; da Silva, SB; de L Alves, SM; Dos Anjos, JV; Feitosa, SGD; Santos, RCA | 1 |
| Amorim, AC; Antunes, E; Britto-Júnior, J; Campos, R; da Silva-Filho, WP; De Nucci, G; Fregonesi, A; Monica, FZ; Moraes, MEA; Moraes, MO | 1 |
| Baldassarri, V; Cicione, A; D'Annunzio, S; DE Nunzio, C; Franco, A; Guarnotta, G; Lombardo, R; Mancini, E; Nacchia, A; Rovesti, LM; Tema, G; Tubaro, A; Voglino, OA | 1 |
51 review(s) available for doxazosin and prazosin
| Article | Year |
|---|---|
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
Topics: Animals; Humans; Molecular Biology; Molecular Structure; Radioligand Assay; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta | 1995 |
Pharmacological options in the treatment of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Controlled Clinical Trials as Topic; Endothelins; Enzyme Inhibitors; Humans; Male; Prostate; Prostatic Hyperplasia; Receptors, Adrenergic, alpha; Structure-Activity Relationship | 1997 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Prostatic adenoma: new drugs, new surgical techniques].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Androstenes; Azasteroids; Cystoscopes; Doxazosin; Finasteride; Humans; Male; Prazosin; Prostatectomy; Prostatic Hyperplasia; Stents | 1992 |
Doxazosin: a new alpha 1-adrenergic antagonist.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Antihypertensive Agents; Doxazosin; Hemodynamics; Humans; Hypertension; Lipids; Prazosin | 1992 |
The cardiovascular effects of alpha-receptor blocking agents.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Cardiomegaly; Cardiovascular System; Cost-Benefit Analysis; Doxazosin; Humans; Hypertension; Lipids; Prazosin | 1992 |
Alpha-blocker therapy of hypertension. An unfulfilled promise.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Hypertension; Lipids; Prazosin | 1991 |
The value of alpha-blockers in the management of hypertension: a practical view.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Pressure; Coronary Disease; Doxazosin; Humans; Hypotension, Orthostatic; Lipids; Posture; Prazosin; Risk Factors; Smoking | 1991 |
Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism.
Topics: Antihypertensive Agents; Cholesterol; Clinical Trials as Topic; Coronary Disease; Doxazosin; Humans; Hypertension; Lipids; Prazosin; Prospective Studies; Risk Factors | 1991 |
Efficacy of doxazosin in specific hypertensive patient groups.
Topics: Adrenal Gland Neoplasms; Antihypertensive Agents; Cardiomegaly; Diabetes Mellitus, Type 2; Doxazosin; Humans; Hyperlipidemias; Hypertension; Kidney Failure, Chronic; Lung Diseases, Obstructive; Pheochromocytoma; Prazosin; Smoking; Vascular Diseases | 1991 |
Doxazosin therapy in the treatment of diabetic hypertension.
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Doxazosin; Humans; Hypertension; Lipids; Lipoproteins; Prazosin; Risk Factors | 1991 |
New drugs for hypertension--variations on old themes.
Topics: Amlodipine; Antihypertensive Agents; Delayed-Action Preparations; Dihydropyridines; Doxazosin; Humans; Hypertension; Isradipine; Nifedipine; Prazosin; Verapamil | 1991 |
Efficacy and tolerance of doxazosin: a review.
Topics: Blood Pressure; Cholesterol; Double-Blind Method; Doxazosin; Forecasting; Humans; Hypertension; Lipoproteins, HDL; Posture; Prazosin | 1990 |
Comparison of pharmacokinetics and pharmacodynamics of adrenoceptor agonists and antagonists as antihypertensive agents.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Blood Pressure; Clonidine; Doxazosin; Humans; Hypertension; Prazosin | 1987 |
Factors influencing the lipid response to selective alpha 1-inhibition.
Topics: Adrenergic alpha-Antagonists; Animals; Cholesterol; Cholesterol, Dietary; Diet; Doxazosin; Humans; Hypertension; Lipid Metabolism; Lipoprotein Lipase; Lipoproteins, LDL; Nutritional Status; Prazosin; Species Specificity | 1989 |
[New specialty drugs registered in Austria. Supressin].
Topics: Antihypertensive Agents; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Humans; Hypertension; Prazosin | 1989 |
Clinical pharmacotherapeutics of doxazosin.
Topics: Adrenergic alpha-Antagonists; Coronary Disease; Doxazosin; Hemodynamics; Humans; Hypertension; Prazosin; Risk | 1989 |
Pharmacologic basis for the use of doxazosin in the treatment of essential hypertension.
Topics: Adrenergic alpha-Antagonists; Animals; Doxazosin; Hemodynamics; Humans; Hypertension; Muscle, Smooth, Vascular; Prazosin | 1989 |
Review of the effects of doxazosin, a new selective alpha 1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Doxazosin; Humans; Hydrochlorothiazide; Hypertension; Lipoproteins; Prazosin | 1989 |
alpha 1-antagonists in the treatment of hypertension.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Pressure; Doxazosin; Humans; Hypertension; Prazosin | 1989 |
Mechanism of alpha blockade for blood pressure control.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Calcium Channel Blockers; Doxazosin; Endothelium; Norepinephrine; Prazosin; Receptors, Adrenergic, alpha | 1987 |
Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Clinical Trials as Topic; Dogs; Doxazosin; Hemodynamics; Humans; Hypertension; Kidney; Mice; Prazosin; Rats | 1988 |
Pharmacotherapeutic stature of doxazosin and its role in coronary risk reduction.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Coronary Disease; Dose-Response Relationship, Drug; Doxazosin; Hemodynamics; Humans; Hypertension; Lipids; Prazosin; Risk | 1988 |
Implications of doxazosin therapy on risk of coronary heart disease.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Coronary Disease; Doxazosin; Humans; Lipoproteins; Prazosin; Risk | 1988 |
Doxazosin, a case history.
Topics: Animals; Doxazosin; Humans; Prazosin; Vasodilator Agents | 1986 |
[Therapy of benign prostatic hyperplasia with alpha receptor blockers].
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Male; Prazosin; Prostatic Hyperplasia; Receptors, Adrenergic, alpha-1; Treatment Outcome; Urinary Bladder Neck Obstruction; Urodynamics | 1995 |
Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience.
Topics: Adrenergic alpha-Antagonists; Blood Pressure; Clinical Trials as Topic; Doxazosin; Half-Life; Humans; Male; Prazosin; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Vasodilation | 1996 |
[Alpha-blocker].
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Antihypertensive Agents; Diagnosis, Differential; Doxazosin; Humans; Hypertension; Pheochromocytoma; Prazosin | 1995 |
Measures of Proscar, Hytrin, and Cardura side effects.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia | 1997 |
Prostatic alpha 1-adrenoceptors and uroselectivity.
Topics: Adrenergic alpha-Antagonists; Animals; Doxazosin; Humans; Male; Prazosin; Prostate; Quinazolines; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin | 1997 |
[Alpha blockers in the treatment of benign hyperplasia of the prostate].
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Indoramin; Male; Phenoxybenzamine; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 1997 |
Pharmacotherapy for benign prostatic hyperplasia--the potential for alpha 1-adrenoceptor subtype-specific blockade.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Hormones; Humans; Male; Patient Selection; Plant Extracts; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 1998 |
Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonist.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Humans; Male; Prazosin; Prostatic Hyperplasia; Sulfonamides; Tamsulosin | 1998 |
A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Controlled Clinical Trials as Topic; Dizziness; Dose-Response Relationship, Drug; Doxazosin; Humans; Hypotension, Orthostatic; Male; Middle Aged; Prazosin; Prognosis; Prostatic Hyperplasia; Quinazolines; Treatment Outcome; Urologic Diseases | 1999 |
Medical therapy for benign prostatic hyperplasia: a review of the literature.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Finasteride; Humans; Indoramin; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 2000 |
[Drugs for the treatment of benign prostatic hypertrophy].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Aged; Androgen Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Middle Aged; Muscle, Smooth; Plant Extracts; Prazosin; Prostatic Hyperplasia; Receptors, Adrenergic, alpha-1; Serenoa; Sulfonamides; Tamsulosin; Urinary Bladder Neck Obstruction; Urodynamics | 2000 |
Terazosin, doxazosin, and prazosin: current clinical experience.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Doxazosin; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Receptors, Adrenergic, alpha | 2001 |
Induction of apoptosis in the prostate by alpha1-adrenoceptor antagonists: a novel effect of "old" drugs.
Topics: Adrenergic alpha-Antagonists; Apoptosis; Doxazosin; Humans; Male; Prazosin; Prostatic Hyperplasia; Tumor Cells, Cultured | 2000 |
Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
Topics: Adrenergic alpha-Antagonists; Apoptosis; Doxazosin; Humans; Male; Prazosin; Prostate; Prostatic Hyperplasia; Structure-Activity Relationship; Treatment Outcome; Urinary Bladder Neck Obstruction | 2003 |
The role of combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Disease Progression; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia; Treatment Outcome | 2003 |
[Pharmacologic treatment of benign prostatic hyperplasia].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Phytotherapy; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 2003 |
Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Doxazosin; Humans; Male; Prazosin; Prostatic Hyperplasia; Prostatic Neoplasms; Quinazolines | 2004 |
The role of alpha-blockers in the management of prostate cancer.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Angiogenesis Inhibitors; Anoikis; Doxazosin; Humans; Male; Prazosin; Prostatic Neoplasms; Quinazolines; Sulfonamides; Tamsulosin | 2004 |
Treatment and pharmacologic management of BPH in the context of common comorbidities.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Azasteroids; Cardiovascular Diseases; Comorbidity; Doxazosin; Drug Therapy, Combination; Dutasteride; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Global Health; Humans; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Transurethral Resection of Prostate; Treatment Outcome | 2006 |
[Alpha blockers in use for symptomatic benign prostatic hyperplasia--are all drugs born equal?].
Topics: Adrenergic alpha-Antagonists; Doxazosin; Evidence-Based Medicine; Humans; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 2008 |
Risk factors for intraoperative floppy iris syndrome: a meta-analysis.
Topics: Adrenergic alpha-1 Receptor Antagonists; Diabetes Complications; Doxazosin; Humans; Hypertension; Incidence; Intraoperative Complications; Iris; Iris Diseases; Odds Ratio; Phacoemulsification; Prazosin; Quinazolines; Risk Factors; Sulfonamides; Syndrome; Tamsulosin | 2011 |
[How effective is finasteride?].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Quality of Life; Sulfonamides; Tamsulosin | 2011 |
α1-Blockers Improve Benign Prostatic Obstruction in Men with Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis of Urodynamic Studies.
Topics: Adrenergic alpha-1 Receptor Antagonists; Clinical Trials as Topic; Doxazosin; Humans; Indoles; Male; Naphthalenes; Piperazines; Prazosin; Prostatism; Quinazolines; Severity of Illness Index; Sulfonamides; Tamsulosin; Urodynamics | 2016 |
The Role of α1-Adrenoceptor Antagonists in the Treatment of Prostate and Other Cancers.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Antineoplastic Agents; Doxazosin; Female; Humans; Male; Prazosin; Prostatic Neoplasms | 2016 |
Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with α-blockers.
Topics: Adrenergic alpha-Antagonists; Dizziness; Doxazosin; Humans; Hypotension; Lower Urinary Tract Symptoms; Male; Prazosin; Prostatic Hyperplasia; Randomized Controlled Trials as Topic | 2016 |
Alpha-blockers after shock wave lithotripsy for renal or ureteral stones in adults.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Chemotherapy, Adjuvant; Combined Modality Therapy; Doxazosin; Humans; Indoles; Kidney Calculi; Lithotripsy; Middle Aged; Prazosin; Quinazolines; Randomized Controlled Trials as Topic; Tamsulosin; Ureteral Calculi | 2020 |
102 trial(s) available for doxazosin and prazosin
| Article | Year |
|---|---|
Increase in serum total angiotensin-converting enzyme activity with enalapril therapy in humans: a controlled trial.
Topics: Double-Blind Method; Doxazosin; Drug Administration Schedule; Enalapril; Female; Humans; Hypertension; Male; Middle Aged; Peptidyl-Dipeptidase A; Prazosin; Renin-Angiotensin System | 1992 |
Doxazosin: a new alpha 1-adrenergic antagonist.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Antihypertensive Agents; Doxazosin; Hemodynamics; Humans; Hypertension; Lipids; Prazosin | 1992 |
Doxazosin in the management of hypertensive diabetes--a cautionary note (?).
Topics: Antihypertensive Agents; Diabetes Complications; Diabetes Mellitus; Doxazosin; Humans; Hypertension; Middle Aged; Prazosin | 1992 |
A double-blind comparative study of doxazosin and prazosin when administered with beta-blockers or diuretics.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Coronary Disease; Diuretics; Double-Blind Method; Doxazosin; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Netherlands; Prazosin; Risk Factors | 1991 |
The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by beta-blockers.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Doxazosin; Drug Therapy, Combination; Female; Humans; Hypertension; Lipids; Male; Middle Aged; Prazosin; Time Factors | 1991 |
Doxazosin for the treatment of chronic congestive heart failure: results of a randomized double-blind and placebo-controlled study.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Doxazosin; Exercise; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Prazosin; Quality of Life | 1991 |
[Comparative effects of doxazosin and enalapril in patients with arterial hypertension and exercise-induced acute myocardial ischemia].
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Coronary Disease; Doxazosin; Enalapril; Exercise Test; Female; Humans; Hypertension; Male; Middle Aged; Prazosin; Vasodilator Agents | 1991 |
Synergism between alpha 1-blockade and angiotensin converting enzyme inhibition in essential hypertension.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Double-Blind Method; Doxazosin; Drug Synergism; Drug Therapy, Combination; Enalapril; Humans; Hypertension; Prazosin | 1991 |
Vascular pressor responses in treated and untreated essential hypertension.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Antihypertensive Agents; Blood Pressure; Catecholamines; Doxazosin; Enalapril; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Nifedipine; Peptidyl-Dipeptidase A; Phenylephrine; Prazosin; Reflex; Regional Blood Flow; Renin | 1990 |
Preliminary results of the Norwegian doxazosin postmarketing surveillance study: a twelve-week experience.
Topics: Antihypertensive Agents; Blood Pressure; Cholesterol; Coronary Disease; Doxazosin; Female; Heart Rate; Humans; Hypertension; Lipids; Male; Middle Aged; Norway; Prazosin; Product Surveillance, Postmarketing; Risk Factors; Time Factors | 1991 |
Doxazosin: a study in a cohort of patients with hypertension in general practice--an interim report.
Topics: Antihypertensive Agents; Cholesterol; Cohort Studies; Coronary Disease; Doxazosin; England; Family Practice; Female; Humans; Hypertension; Male; Middle Aged; Prazosin; Risk Factors; Smoking | 1991 |
An open, noncomparative study of doxazosin in essential hypertension: experience in general practice in The Netherlands.
Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Doxazosin; Family Practice; Female; Humans; Hypertension; Lipids; Male; Middle Aged; Netherlands; Prazosin; Risk Factors | 1991 |
Doxazosin and atenolol as monotherapy in mild and moderate hypertension: a randomized, parallel study with a three-year follow-up.
Topics: Antihypertensive Agents; Atenolol; Cholesterol; Coronary Disease; Double-Blind Method; Doxazosin; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Norway; Prazosin; Risk Factors; Time Factors | 1991 |
Double-blind comparison of doxazosin and enalapril in patients with mild or moderate essential hypertension.
Topics: Antihypertensive Agents; Coronary Disease; Double-Blind Method; Doxazosin; Enalapril; Family Practice; Female; Germany, West; Humans; Hypertension; Lipids; Male; Middle Aged; Prazosin; Risk Factors | 1991 |
A double-blind comparative study of doxazosin and prazosin in the treatment of essential hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Double-Blind Method; Doxazosin; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Prazosin | 1991 |
Clinical experience with doxazosin in general medical practice in New Zealand.
Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Doxazosin; Family Practice; Female; Humans; Hypertension; Lipids; Male; Middle Aged; New Zealand; Prazosin; Product Surveillance, Postmarketing; Risk Factors | 1991 |
Doxazosin in the treatment of essential hypertension in general medical practice in Latin America.
Topics: Antihypertensive Agents; Argentina; Cholesterol; Coronary Disease; Doxazosin; Family Practice; Female; Humans; Hypertension; Lipids; Male; Middle Aged; Prazosin; Risk Factors; Venezuela | 1991 |
A multicenter study of doxazosin in the treatment of essential hypertension in France.
Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Doxazosin; Family Practice; Female; France; Humans; Hypertension; Male; Middle Aged; Prazosin; Risk Factors | 1991 |
Clinical experience with doxazosin in general medical practice in The Netherlands.
Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Doxazosin; Family Practice; Female; Humans; Hypertension; Male; Middle Aged; Netherlands; Prazosin; Risk Factors | 1991 |
A long-term study of doxazosin in the treatment of mild or moderate essential hypertension in general medical practice.
Topics: Antihypertensive Agents; Cholesterol; Doxazosin; Drug Therapy, Combination; Family Practice; Female; Humans; Hypertension; Male; Middle Aged; Prazosin; Time Factors | 1991 |
Doxazosin in the treatment of mild or moderate essential hypertension: an echocardiographic study.
Topics: Adult; Antihypertensive Agents; Cardiomegaly; Doxazosin; Echocardiography; Female; Humans; Hypertension; Male; Prazosin | 1991 |
Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension.
Topics: Antihypertensive Agents; Cardiomegaly; Cholesterol; Coronary Disease; Doxazosin; Echocardiography; Female; Humans; Hypertension; Lipids; Male; Middle Aged; Prazosin; Risk Factors; Venezuela | 1991 |
Efficacy and safety of doxazosin in the treatment of patients with mild or moderate essential hypertension and elevated levels of cholesterol.
Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Doxazosin; England; Female; Humans; Hypertension; Male; Middle Aged; Prazosin; Risk Factors; Single-Blind Method | 1991 |
A multicenter study of doxazosin in the treatment of patients with mild or moderate essential hypertension and concomitant intermittent claudication.
Topics: Antihypertensive Agents; Doxazosin; Female; Humans; Hypertension; Intermittent Claudication; Male; Middle Aged; Prazosin; Regional Blood Flow | 1991 |
An evaluation of the efficacy and safety of doxazosin in hypertension associated with renal dysfunction. The Japanese Doxazosin Study Group.
Topics: Adult; Aged; Antihypertensive Agents; Doxazosin; Drug Therapy, Combination; Female; Humans; Hypertension, Renal; Male; Middle Aged; Prazosin | 1991 |
Evidence of an antiplatelet aggregation action of doxazosin in patients with hypertension: an ex vivo study.
Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Doxazosin; Female; Humans; Hypertension; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prazosin; Risk Factors; Single-Blind Method; Thromboembolism | 1991 |
Effects of doxazosin on blood pressure, renin-angiotensin-aldosterone and urinary kallikrein.
Topics: Adult; Antihypertensive Agents; Double-Blind Method; Doxazosin; Drug Administration Schedule; Female; Humans; Hypertension; Kallikreins; Male; Middle Aged; Natriuresis; Prazosin; Renin-Angiotensin System | 1991 |
Doxazosin effects on insulin and glucose in hypertensive patients. The Finnish Multicenter Study Group.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Doxazosin; Female; Finland; Humans; Hypertension; Insulin; Lipids; Male; Middle Aged; Prazosin | 1991 |
Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Body Weight; Double-Blind Method; Doxazosin; Female; Fibrinolysis; Heart Rate; Humans; Hypercholesterolemia; Hypertension; Male; Plasminogen Inactivators; Prazosin; Randomized Controlled Trials as Topic; Risk Factors; Tissue Plasminogen Activator | 1991 |
Dose-response clarification in early drug development.
Topics: Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Doxazosin; Enalapril; Humans; Hypertension; Nifedipine; Prazosin | 1991 |
Doxazosin in 'resistant' hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Diuretics; Doxazosin; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Prazosin | 1990 |
Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects.
Topics: Adrenergic alpha-Antagonists; Aged; Atenolol; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Doxazosin; Female; Glucose; Humans; Hypertension; Lipoproteins; Male; Middle Aged; Prazosin | 1990 |
Acute effects of doxazosin and atenolol on smoking-induced peripheral vasoconstriction in hypertensive habitual smokers.
Topics: Adrenergic alpha-Antagonists; Adult; Atenolol; Double-Blind Method; Doxazosin; Female; Humans; Hypertension; Injections, Intravenous; Male; Middle Aged; Plethysmography; Prazosin; Skin; Smoking; Thermography; Ultrasonography; Vascular Resistance; Vasoconstriction | 1990 |
Blood pressure and heart rate response to repeated smoking before and after beta-blockade and selective alpha 1 inhibition.
Topics: Adrenergic alpha-Antagonists; Adult; Atenolol; Blood Pressure; Doxazosin; Heart Rate; Humans; Hypertension; Prazosin; Single-Blind Method; Smoking | 1990 |
Long-term effects of doxazosin and atenolol on serum lipids and blood pressure in hypertensive smokers.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Atenolol; Double-Blind Method; Doxazosin; Female; Hemodynamics; Humans; Hypertension; Lipids; Male; Middle Aged; Prazosin; Retrospective Studies; Smoking | 1990 |
Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Doxazosin; Drug Therapy, Combination; Humans; Hypertension; Middle Aged; Prazosin | 1990 |
Efficacy and tolerance of doxazosin: a review.
Topics: Blood Pressure; Cholesterol; Double-Blind Method; Doxazosin; Forecasting; Humans; Hypertension; Lipoproteins, HDL; Posture; Prazosin | 1990 |
A long-term study of atenolol and doxazosin in mild and moderate hypertension.
Topics: Adolescent; Adult; Aged; Atenolol; Blood Pressure; Cholesterol; Double-Blind Method; Doxazosin; Female; Humans; Hypertension; Male; Middle Aged; Prazosin; Risk Factors; Time Factors; Triglycerides | 1990 |
An evaluation of the efficacy and safety of doxazosin in the treatment of hypertension associated with renal insufficiency.
Topics: Acute Kidney Injury; Adult; Blood Pressure; Doxazosin; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Prazosin; Single-Blind Method | 1990 |
Antihypertensive effect of doxazosin and atenolol in short- and long-term double-blind comparison.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Doxazosin; Drug Administration Schedule; Female; Heart Rate; Humans; Hypertension; Lipids; Male; Middle Aged; Prazosin; Regression Analysis | 1990 |
Short-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Prazosin; Random Allocation; Regression Analysis | 1988 |
Long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Chemical Analysis; Blood Pressure; Double-Blind Method; Doxazosin; Female; Heart Rate; Humans; Hypertension; Lipids; Male; Middle Aged; Prazosin; Random Allocation; Time Factors | 1989 |
Comparison of doxazosin and atenolol in mild hypertension, and effects on exercise capacity, hemodynamics and left ventricular function.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Female; Heart; Heart Rate; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Physical Exertion; Prazosin; Radionuclide Imaging | 1989 |
Effectiveness of doxazosin in systemic hypertension.
Topics: Adult; Antihypertensive Agents; Body Weight; Double-Blind Method; Doxazosin; Drug Administration Schedule; Heart Rate; Humans; Hypertension; Male; Multicenter Studies as Topic; Prazosin; Random Allocation; Supination | 1989 |
[New specialty drugs registered in Austria. Supressin].
Topics: Antihypertensive Agents; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Humans; Hypertension; Prazosin | 1989 |
Concentration-effect relationships and individual responses to doxazosin in essential hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Doxazosin; Female; Heart Rate; Humans; Hypertension; Injections, Intravenous; Male; Middle Aged; Norepinephrine; Phenylephrine; Prazosin | 1989 |
Alpha-1 adrenoceptor blockade with doxazosin in hypertension: effects on blood pressure and lipoproteins.
Topics: Adrenergic alpha-Antagonists; Adult; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Female; Heart Rate; Humans; Hypertension; Lipids; Lipoproteins; Male; Prazosin; Random Allocation | 1989 |
alpha 1-antagonists in the treatment of hypertension.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Pressure; Doxazosin; Humans; Hypertension; Prazosin | 1989 |
Human vascular smooth muscle responses mediated by alpha 2 mechanisms in vivo and in vitro.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adult; Arteries; Brimonidine Tartrate; Dioxanes; Doxazosin; Forearm; Humans; Idazoxan; In Vitro Techniques; Male; Muscle Contraction; Muscle, Smooth, Vascular; Prazosin; Quinoxalines; Receptors, Adrenergic, alpha | 1985 |
Effects of oral antihypertensive agents on blood lipid levels.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Coronary Disease; Diuretics; Double-Blind Method; Doxazosin; Humans; Hypercholesterolemia; Hypertension; Lipids; Male; Middle Aged; Pindolol; Prazosin; Prospective Studies; Risk | 1986 |
Efficacy and safety of doxazosin in hypertension therapy.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Female; Heart Rate; Humans; Hypertension; Lipids; Male; Middle Aged; Prazosin | 1987 |
A multicenter trial of doxazosin in West Germany.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Clinical Trials as Topic; Doxazosin; Female; Humans; Hypertension; Male; Middle Aged; Prazosin | 1987 |
Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Double-Blind Method; Doxazosin; Humans; Hydrochlorothiazide; Hypertension; Lipids; Placebos; Prazosin | 1987 |
Serum lipid changes in a one-year, multicenter, double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Female; Heart Rate; Humans; Hypertension; Lipids; Male; Middle Aged; Prazosin; Random Allocation; Time Factors | 1987 |
An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Female; Heart Rate; Humans; Hypertension; Lipids; Male; Middle Aged; Prazosin | 1987 |
Multicenter, double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Female; Heart Rate; Humans; Hypertension; Lipoproteins; Male; Middle Aged; Prazosin | 1987 |
Effects of alpha 1 inhibition on renal blood flow and sympathetic nervous activity in systemic hypertension.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Dopamine beta-Hydroxylase; Doxazosin; Female; Humans; Hypertension; Male; Middle Aged; Norepinephrine; Prazosin; Random Allocation; Renal Circulation; Renin; Sympathetic Nervous System; Vascular Resistance | 1987 |
A double-blind parallel trial to assess the efficacy of doxazosin, atenolol and placebo in patients with mild to moderate systemic hypertension.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Heart Rate; Humans; Hypertension; Lipids; Placebos; Prazosin; Random Allocation | 1987 |
Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Female; Humans; Hypertension; Male; Middle Aged; Prazosin | 1987 |
Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Female; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Lipids; Male; Middle Aged; Prazosin; Prospective Studies; Random Allocation | 1987 |
Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Clinical Trials as Topic; Dogs; Doxazosin; Hemodynamics; Humans; Hypertension; Kidney; Mice; Prazosin; Rats | 1988 |
A multicenter study of doxazosin in the treatment of severe essential hypertension.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Doxazosin; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Multicenter Studies as Topic; Prazosin | 1988 |
Doxazosin: a newly developed, selective alpha 1-inhibitor in the management of patients with pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Catecholamines; Doxazosin; Female; Humans; Hypertension; Male; Middle Aged; Pheochromocytoma; Prazosin | 1988 |
Comparison of the effects of doxazosin and atenolol on blood pressure and blood lipids: a one-year, double-blind study in 228 hypertensive patients.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Coronary Disease; Double-Blind Method; Doxazosin; Female; Humans; Hypertension; Lipids; Male; Middle Aged; Prazosin | 1988 |
Doxazosin versus atenolol: a randomized comparison of calculated coronary heart disease risk reduction.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Disease; Doxazosin; Female; Heart Rate; Humans; Lipids; Male; Middle Aged; Prazosin; Random Allocation; Risk | 1988 |
A comparative study of doxazosin versus atenolol in mild-to-moderate hypertension.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Doxazosin; Electrocardiography; Female; Humans; Hypertension; Lipids; Male; Middle Aged; Prazosin | 1988 |
A double-blind comparative study of doxazosin and nitrendipine in patients with mild-to-moderate essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease; Double-Blind Method; Doxazosin; Female; Heart Rate; Humans; Hypertension; Lipids; Male; Middle Aged; Nitrendipine; Prazosin | 1988 |
A comparison of doxazosin and enalapril in the treatment of mild and moderate essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Doxazosin; Enalapril; Female; Humans; Hypertension; Lipids; Male; Middle Aged; Prazosin | 1988 |
Alpha-adrenoceptors and the kidney.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Hypertension; Kidney; Prazosin; Receptors, Adrenergic, alpha; Renal Circulation; Renin; Yohimbine | 1988 |
A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Female; Heart Rate; Humans; Hypertension; Kinetics; Lipids; Male; Middle Aged; Prazosin; Random Allocation | 1986 |
Antihypertensive effect of doxazosin in hypertensive patients: comparison with atenolol.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Prazosin; Random Allocation | 1986 |
Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Body Weight; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Female; Humans; Hypertension; Lipids; Male; Middle Aged; Prazosin; Random Allocation | 1986 |
Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins.
Topics: Adult; Aged; Antihypertensive Agents; Apolipoproteins; Atenolol; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Female; Humans; Hypertension; Lipids; Lipoproteins; Male; Middle Aged; Prazosin; Random Allocation; Time Factors; Triglycerides | 1986 |
The antihypertensive effects of doxazosin: a clinical overview.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Female; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Kinetics; Male; Metoprolol; Middle Aged; Nadolol; Prazosin; Propanolamines; Random Allocation; Risk; Triglycerides | 1986 |
Effect of doxazosin on blood pressure and renal haemodynamics of hypertensive patients with renal failure.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Doxazosin; Female; Humans; Hypertension, Renal; Male; Middle Aged; Prazosin; Renal Circulation | 1986 |
Clinical pharmacology of doxazosin in patients with essential hypertension.
Topics: Adult; Blood Pressure; Blood Proteins; Doxazosin; Female; Half-Life; Heart Rate; Humans; Hypertension; Kinetics; Male; Middle Aged; Prazosin; Random Allocation | 1987 |
The pharmacokinetics and pharmacodynamics of doxazosin compared with atenolol during long-term double-blind treatment.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Female; Heart Rate; Humans; Hypertension; Kinetics; Male; Middle Aged; Prazosin; Random Allocation | 1987 |
A 24-week multicenter double-blind study of doxazosin and hydrochlorothiazide in patients with mild to moderate essential hypertension.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Female; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Lipids; Male; Middle Aged; Prazosin; Random Allocation; Time Factors | 1987 |
Acute haemodynamic and hormonal effects of oral doxazosin in normal subjects.
Topics: Administration, Oral; Adult; Aldosterone; Antihypertensive Agents; Doxazosin; Hemodynamics; Humans; Hydrocortisone; Male; Prazosin; Renin | 1987 |
[Doxazosin and nitrendipine. A double-blind comparative study in patients with mild to moderate hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Female; Humans; Hypertension; Male; Middle Aged; Nitrendipine; Prazosin | 1987 |
A double-blind and cross-over comparison of once daily doxazosin and placebo with steady-state pharmacokinetics in elderly hypertensive patients.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Electrocardiography; Female; Humans; Hypertension; Male; Placebos; Prazosin; Pulse; Random Allocation | 1988 |
Effect of doxazosin monotherapy on blood pressure and plasma lipids in patients with essential hypertension.
Topics: Blood Pressure; Doxazosin; Female; Heart Rate; Humans; Hypertension; Lipids; Male; Middle Aged; Norepinephrine; Prazosin | 1988 |
24-hour control of blood pressure by once daily doxazosin: a multicentre double-blind comparison with placebo.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Female; Humans; Hypertension; Male; Middle Aged; Prazosin | 1988 |
Doxazosin in patients with hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Doxazosin; Female; Half-Life; Heart Rate; Humans; Hypertension; Male; Middle Aged; Prazosin | 1988 |
Vascular alpha-adrenoceptors in man: interactions with adrenaline and noradrenaline.
Topics: Adult; Doxazosin; Epinephrine; Forearm; Humans; Male; Muscle, Smooth, Vascular; Norepinephrine; Prazosin; Propranolol; Receptors, Adrenergic, alpha; Vasoconstriction; Yohimbine | 1985 |
A pharmacodynamic and pharmacokinetic assessment of a new alpha-adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects.
Topics: Adrenergic alpha-Antagonists; Adult; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Doxazosin; Heart Rate; Humans; Kinetics; Male; Prazosin; Quinazolines | 1982 |
Within patient comparison of prazosin and UK-33,274. A new alpha-adrenoceptor-antagonist.
Topics: Adrenergic alpha-Antagonists; Adult; Antihypertensive Agents; Blood Pressure; Doxazosin; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Posture; Prazosin; Quinazolines; Time Factors | 1982 |
Doxazosin, an alpha 1-adrenoceptor antagonist: pharmacokinetics and concentration-effect relationships in man.
Topics: Adrenergic alpha-Antagonists; Adult; Blood Pressure; Dose-Response Relationship, Drug; Doxazosin; Half-Life; Heart Rate; Humans; Kinetics; Male; Phenylephrine; Prazosin; Quinazolines | 1983 |
Postjunctional selectivity of alpha-blockade with prazosin, trimazosin, and UK-33,274 in man.
Topics: Adrenergic alpha-Antagonists; Adult; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Doxazosin; Heart Rate; Humans; Male; Norepinephrine; Phenylephrine; Piperazines; Prazosin; Quinazolines | 1982 |
Doxazosin--an alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (Part One).
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Doxazosin; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Treatment Outcome; Urodynamics | 1995 |
Terazosin and doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Doxazosin; Drug Administration Schedule; Humans; Male; Middle Aged; Pilot Projects; Prazosin; Prostatic Hyperplasia; Urodynamics | 1995 |
Doxazosin--an alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (BPH) (Part Two).
Topics: Acid Phosphatase; Adrenergic alpha-Antagonists; Creatinine; Doxazosin; Humans; Male; Prazosin; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Time Factors | 1995 |
Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Arteries; Blood Pressure; Cholesterol; Doxazosin; Female; Heart Rate; Humans; Hypertension; In Vitro Techniques; Lipids; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prazosin; Triglycerides | 1996 |
Pharmacokinetic interaction between finasteride and terazosin, but not finasteride and doxazosin.
Topics: Adrenergic alpha-Antagonists; Adult; Area Under Curve; Doxazosin; Drug Interactions; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prazosin; Time Factors | 1998 |
[Management of hypertensive patients with left ventricular hypertrophy].
Topics: Adrenergic alpha-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Doxazosin; Drug Therapy, Combination; Echocardiography; Electrocardiography; Enalapril; Humans; Hypertension; Hypertrophy, Left Ventricular; Indapamide; Placebos; Prazosin; Prognosis; Prospective Studies; Risk Factors; Time Factors | 2002 |
Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Biopsy; Brachytherapy; Doxazosin; Follow-Up Studies; Humans; Iodine Radioisotopes; Male; Palladium; Postoperative Complications; Prazosin; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiotherapy, Conformal; Sulfonamides; Tamsulosin; Treatment Outcome; Urinary Retention; Urination Disorders | 2002 |
Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia.
Topics: Clinical Trials as Topic; Doxazosin; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Sulfonamides; Tamsulosin | 2004 |
Terazosin and doxazosin in the treatment of BPH: results of a randomized study with crossover in non-responders.
Topics: Adrenergic alpha-Antagonists; Aged; Cross-Over Studies; Doxazosin; Humans; Male; Middle Aged; Prazosin; Prospective Studies; Prostatic Hyperplasia | 2004 |
The comparison and efficacy of 3 different alpha1-adrenergic blockers for distal ureteral stones.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Doxazosin; Female; Humans; Male; Middle Aged; Pain Measurement; Prazosin; Sulfonamides; Tamsulosin; Treatment Outcome; Ureteral Calculi | 2005 |
[Comparison of different drugs on the treatment of benign prostate hyperplasia].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Androstadienes; Double-Blind Method; Doxazosin; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Plant Extracts; Prazosin; Prostate; Prostatic Hyperplasia; Quality of Life; Secale; Sulfonamides; Tamsulosin; Treatment Outcome | 2007 |
[Efficacy of monotherapy with 15 antihypertensive agents in treating essential hypertension assessed by 24-hour ambulatory blood pressure monitoring].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Doxazosin; Drug Therapy, Combination; Humans; Hypertension; Prazosin; Sulfonamides; Torsemide; Treatment Outcome | 2007 |
Comparison of 7 α(1)-adrenoceptor antagonists in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia:a short-term crossover study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Doxazosin; Humans; Indoles; Lower Urinary Tract Symptoms; Male; Middle Aged; Naphthalenes; Piperazines; Prazosin; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Treatment Outcome | 2013 |
189 other study(ies) available for doxazosin and prazosin
| Article | Year |
|---|---|
2,4-diamino-6,7-dimethoxyquinazolines. 1. 2-[4-(1,4-benzodioxan-2-ylcarbonyl)piperazin-1-yl] derivatives as alpha 1-adrenoceptor antagonists and antihypertensive agents.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Brain; Dioxanes; Dioxins; Heart Rate; Hypertension; Indicators and Reagents; Models, Molecular; Piperazines; Rats; Rats, Inbred SHR; Receptors, Adrenergic, alpha; Structure-Activity Relationship | 1987 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Range and sensitivity as descriptors of molecular property spaces in dynamic QSAR analyses.
Topics: Chemical Phenomena; Chemistry, Physical; Ligands; Models, Molecular; Molecular Conformation; Monte Carlo Method; Quantitative Structure-Activity Relationship; Receptors, Adrenergic, alpha-1; Solvents | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Computational approach to the basicity of a series of alpha1-adrenoceptor ligands in aqueous solution.
Topics: Chemical Phenomena; Chemistry, Physical; Computational Biology; Databases, Factual; Epinephrine; Guanidine; Hydrogen-Ion Concentration; Imidazoles; Kinetics; Ligands; Molecular Conformation; Norepinephrine; Receptors, Adrenergic, alpha-1; Solutions; Thermodynamics; Vasoconstrictor Agents; Water | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
Topics: Animals; Cattle; Cell Line; Cell Line, Tumor; Chagas Disease; Drug Evaluation, Preclinical; Hepatocytes; High-Throughput Screening Assays; Humans; Image Processing, Computer-Assisted; Muscle, Skeletal; Parasitic Sensitivity Tests; Trypanocidal Agents; Trypanosoma cruzi | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Quinazoline based α
Topics: Adrenergic alpha-1 Receptor Antagonists; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Male; Molecular Structure; Prostatic Neoplasms; Quinazolines; Receptors, Adrenergic, alpha-1; Structure-Activity Relationship; Tumor Cells, Cultured | 2017 |
Design and synthesis of small molecule agonists of EphA2 receptor.
Topics: Cell Line, Tumor; Dose-Response Relationship, Drug; Doxazosin; Drug Design; Ephrin-A2; Humans; Molecular Docking Simulation; Molecular Structure; Receptor, EphA2; Small Molecule Libraries; Structure-Activity Relationship | 2018 |
A study of the interaction between the hypotensive actions of doxazosin and enalaprilat in anaesthetized rats.
Topics: Anesthesia; Animals; Antihypertensive Agents; Desoxycorticosterone; Disease Models, Animal; Dose-Response Relationship, Drug; Doxazosin; Drug Evaluation, Preclinical; Drug Interactions; Enalaprilat; Female; Hypertension; Prazosin; Rats; Rats, Inbred Strains; Thiopental | 1992 |
[Doxazosin-induced lupus erythematodes].
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Doxazosin; Female; Humans; Lupus Erythematosus, Systemic; Middle Aged; Prazosin | 1992 |
Diurnal exposure profile in rats from dietary administration of a chemical (doxazosin) with a short half-life: interplay of age and diurnal feeding pattern.
Topics: Adrenergic alpha-Antagonists; Aging; Animals; Circadian Rhythm; Dose-Response Relationship, Drug; Doxazosin; Feeding Behavior; Half-Life; Male; Prazosin; Rats; Rats, Inbred Strains; Time Factors | 1992 |
Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin.
Topics: Adrenergic alpha-Antagonists; Adult; Aldosterone; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Catecholamines; Diastole; Dose-Response Relationship, Drug; Doxazosin; Drug Therapy, Combination; Female; Heart Rate; Heart Ventricles; Humans; Hydrochlorothiazide; Hypertension; Lipids; Male; Middle Aged; Organ Size; Prazosin; Renin; Rest; Stress, Physiological; Systole; Time Factors | 1992 |
Dose-related effects of doxazosin on plasma lipids and aortic fatty streak formation in the hypercholesterolemic hamster model.
Topics: Adrenergic alpha-Antagonists; Animals; Aortic Diseases; Arteriosclerosis; Cricetinae; Dose-Response Relationship, Drug; Doxazosin; Hypercholesterolemia; Lipids; Male; Mesocricetus; Prazosin | 1992 |
Combined effect of doxazosin and pindolol on blood pressure control and lipid concentrations in patients with essential hypertension selected from general practice. Hunter Hypertension Research Group.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Doxazosin; Drug Administration Schedule; Drug Therapy, Combination; Family Practice; Female; Humans; Hypertension; Lipids; Male; Middle Aged; Osmolar Concentration; Pindolol; Prazosin | 1992 |
Compliance and reactivity of the peripheral venous system in chronic intermittent hemodialysis.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Compliance; Doxazosin; Female; Humans; Hypertension; Kidney Failure, Chronic; Male; Middle Aged; Nitroglycerin; Plethysmography; Prazosin; Reference Values; Renal Dialysis; Time Factors; Valsalva Maneuver; Veins | 1992 |
Chronic infusion of clonidine does not alleviate spontaneous morphine withdrawal symptoms in rats.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Brimonidine Tartrate; Clonidine; Doxazosin; Drug Implants; Eating; Food; Male; Morphine; Morphine Dependence; Motor Activity; Prazosin; Quinoxalines; Rats; Rats, Inbred Strains; Substance Withdrawal Syndrome | 1992 |
Combination of nifedipine and doxazosin in essential hypertension.
Topics: Aged; Analysis of Variance; Angiotensin II; Antihypertensive Agents; Blood Pressure; Doxazosin; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Nifedipine; Phenylephrine; Prazosin | 1992 |
Vasodilator therapy for acute heart failure: haemodynamic comparison of hydralazine/isosorbide, alpha-adrenoceptor blockade, and angiotensin-converting enzyme inhibition.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiac Output, Low; Doxazosin; Drug Therapy, Combination; Enalaprilat; Heart Rate; Hemodynamics; Humans; Hydralazine; Injections, Intravenous; Isosorbide Dinitrate; Male; Middle Aged; Myocardial Infarction; Prazosin; Pulmonary Wedge Pressure; Vasodilator Agents; Ventricular Function, Left | 1992 |
Doxazosin: alternative antihypertensive treatment.
Topics: Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Doxazosin; Female; Humans; Hypertension; Male; Middle Aged; Prazosin | 1992 |
Amiloride-sensitive lithium reabsorption during doxazosin-induced blood pressure reduction in rats.
Topics: Absorption; Amiloride; Animals; Antihypertensive Agents; Doxazosin; Female; Glomerular Filtration Rate; Kidney; Lithium; Prazosin; Random Allocation; Rats; Rats, Inbred Strains; Sodium; Urination | 1991 |
New alpha 1-adrenergic blocker offers once-daily dosing.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Doxazosin; Humans; Hypertension; Prazosin | 1991 |
Management of coronary heart disease risk factors in hypertensive patients: clinical experience with doxazosin. A symposium. London, England, January 26, 1990. Proceedings.
Topics: Antihypertensive Agents; Coronary Disease; Doxazosin; Humans; Hypertension; Prazosin; Risk Factors | 1991 |
Investigations into interactions between doxazosin and enalaprilat at alpha 1-adrenoceptors in anaesthetized rats.
Topics: Adrenergic alpha-Antagonists; Anesthesia; Angiotensin II; Animals; Desoxycorticosterone; Doxazosin; Drug Interactions; Drug Synergism; Enalaprilat; Female; Phenylephrine; Prazosin; Rats; Rats, Inbred Strains; Receptors, Adrenergic, alpha | 1991 |
Alpha-1 blockade inhibits compensatory sodium reabsorption in the proximal tubules during furosemide-induced volume contraction.
Topics: Adrenergic alpha-Antagonists; Animals; Doxazosin; Drug Interactions; Female; Furosemide; Infusions, Intravenous; Kidney Function Tests; Kidney Tubules, Proximal; Lithium; Prazosin; Rats; Rats, Inbred Strains; Sodium | 1991 |
Validation of a solid-phase extraction high-performance liquid chromatographic assay for doxazosin.
Topics: Adrenergic alpha-Antagonists; Chromatography, High Pressure Liquid; Doxazosin; Humans; Hydrogen-Ion Concentration; Methanol; Prazosin; Propranolol | 1991 |
The effect of doxazosin, urapidil and indoramin pretreatment on fever produced by E. coli lipopolysaccharide in rabbits.
Topics: Adrenergic alpha-Antagonists; Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Temperature Regulation; Doxazosin; Escherichia coli; Female; Fever; Indoramin; Lipopolysaccharides; Male; Piperazines; Prazosin; Rabbits | 1991 |
Effects of adrenoreceptor antagonists and agonists on clearance of emulsion models of triacylglycerol-rich lipoproteins from plasma in rats.
Topics: Adrenergic Agonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Angiotensin II; Animals; Cholesterol Esters; Doxazosin; Emulsions; Fenoterol; Isoproterenol; Lipoprotein Lipase; Lipoproteins; Male; Norepinephrine; Phenylephrine; Prazosin; Propranolol; Rats; Rats, Inbred Strains; Rats, Inbred WKY; Receptors, Adrenergic; Triglycerides | 1991 |
Doxazosin and cholestyramine similarly decrease fatty streak formation in the aortic arch of hyperlipidemic hamsters.
Topics: Adrenergic alpha-Antagonists; Animals; Aorta, Thoracic; Arteriosclerosis; Blood Pressure; Cholesterol; Cholestyramine Resin; Cricetinae; Doxazosin; Heart Rate; Hyperlipidemias; Lipoproteins; Male; Mesocricetus; Prazosin | 1991 |
A norepinephrine-dependent mechanism in the preoptic/anterior hypothalamic area but not in the mediobasal hypothalamus is involved in the regulation of the gonadotropin-releasing hormone pulse generator in ovariectomized rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic alpha-Antagonists; Animals; Doxazosin; Female; Hydroxyindoleacetic Acid; Hypothalamus; Hypothalamus, Anterior; Hypothalamus, Middle; Luteinizing Hormone; Norepinephrine; Ovary; Pituitary Hormone-Releasing Hormones; Prazosin; Preoptic Area; Rats; Secretory Rate | 1990 |
Interactions between enalaprilat and doxazosin at rat tail artery alpha 1-adrenoceptors.
Topics: Adrenergic alpha-Antagonists; Animals; Arteries; Blood Pressure; Desoxycorticosterone; Dose-Response Relationship, Drug; Doxazosin; Drug Interactions; Enalaprilat; Male; Phenylephrine; Prazosin; Rats; Rats, Inbred Strains; Receptors, Adrenergic, alpha; Renin; Tail | 1991 |
Effects of the selective alpha 1-antagonist, doxazosin, on hepatic lipid levels and metabolism in the golden hamster.
Topics: Adrenergic alpha-Antagonists; Animals; Body Weight; Cholesterol; Cricetinae; Doxazosin; Hydroxymethylglutaryl CoA Reductases; Lipase; Lipid Metabolism; Lipoprotein Lipase; Liver; Male; Mesocricetus; Microsomes, Liver; Prazosin; Triglycerides | 1991 |
Blood flow regulation during acute regional ischemia in feline hearts: importance of postjunctional alpha 1- and alpha 2-adrenoceptors.
Topics: Adrenergic alpha-Antagonists; Animals; Benzazepines; Catecholamines; Cats; Coronary Circulation; Coronary Disease; Doxazosin; Heart; Male; Myocardium; Oxygen Consumption; Perfusion; Prazosin; Receptors, Adrenergic, alpha; Vascular Resistance | 1991 |
The effect of doxazosin on platelet aggregation in normotensive subjects and patients with hypertension: an in vitro study.
Topics: Adult; Antihypertensive Agents; Blood Platelets; Dose-Response Relationship, Drug; Doxazosin; Female; Humans; Hypertension; In Vitro Techniques; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prazosin | 1991 |
Doxazosin for treatment of hypertension.
Topics: Antihypertensive Agents; Blood Glucose; Doxazosin; Humans; Hypertension; Lipids; Prazosin | 1991 |
Diabetes mellitus and hypertension: a physiologic basis for a rational therapeutic approach.
Topics: Antihypertensive Agents; Biological Transport; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Doxazosin; Drug Evaluation; Humans; Hydrogen; Hypertension; Lithium; Prazosin; Sodium | 1991 |
[The effect of doxazosin on blood pressure, lipids, fibrinogen and plasminogen activator inhibitor. A comparative study among smokers and non-smokers with essential hypertension].
Topics: Adult; Blood Pressure; Doxazosin; Fibrinogen; Humans; Hypertension; Lipids; Middle Aged; Plasminogen Inactivators; Prazosin; Smoking | 1991 |
Prolonged photostress macular recovery after reduced blood pressure.
Topics: Adaptation, Physiological; Adult; Aerospace Medicine; Antihypertensive Agents; Blood Pressure; Doxazosin; Humans; Hypertension; Intraocular Pressure; Lighting; Macula Lutea; Male; Middle Aged; Prazosin; Reaction Time; Reference Values; Stress, Physiological | 1991 |
The initial hemodynamic response to newer antihypertensive agents at rest and during exercise: review of visacor, doxazosin, nisoldipine, tiapamil, perindoprilat, pinacidil, dilevalol, and carvedilol.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzeneacetamides; Calcium Channel Blockers; Carbazoles; Carvedilol; Doxazosin; Female; Guanidines; Hemodynamics; Humans; Indoles; Labetalol; Male; Middle Aged; Nisoldipine; Pinacidil; Potassium Channels; Prazosin; Propanolamines; Propylamines; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta; Tiapamil Hydrochloride | 1990 |
Binding and functional properties of doxazosin in the human prostate adenoma and canine brain.
Topics: Adenoma; Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Brain; Dogs; Doxazosin; Humans; In Vitro Techniques; Male; Muscle Contraction; Prazosin; Prostate; Prostatic Neoplasms; Receptors, Adrenergic, alpha | 1990 |
The cost-benefit approach to pricing new medicines: doxazosin versus beta-blocker treatment in Sweden.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure; Cholesterol; Cost-Benefit Analysis; Doxazosin; Humans; Hypertension; Lipoproteins, HDL; Male; Middle Aged; Prazosin; Sweden | 1990 |
Regional perfusion in hearts with acute coronary artery occlusion and subsequent beta 2- and alpha 1-adrenergic blockade.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Cats; Coronary Circulation; Coronary Disease; Doxazosin; Drug Interactions; Hemodynamics; Male; Myocardium; Oxygen Consumption; Prazosin; Propanolamines; Renal Circulation; Renin | 1990 |
Hypertension, coronary risk and alpha-blockade.
Topics: Adrenergic alpha-Antagonists; Coronary Disease; Doxazosin; Humans; Hypertension; Prazosin; Risk Factors | 1990 |
Alpha 1-adrenoreceptor blockade and the molecular basis of lipid metabolism alterations.
Topics: Adrenergic alpha-Antagonists; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Doxazosin; Humans; Hypercholesterolemia; Hypertension; Lipoproteins, VLDL; Male; Prazosin; Receptors, LDL; Risk Factors; Triglycerides; Up-Regulation | 1990 |
Selective alpha 1 inhibition with doxazosin in hypertensive smokers and non-smokers: haemodynamic and metabolic effects.
Topics: Adrenergic alpha-Antagonists; Adult; Doxazosin; Female; Fibrinogen; Hemodynamics; Humans; Hypertension; Lipids; Male; Middle Aged; Plasminogen Inactivators; Prazosin; Smoking | 1990 |
The pharmacokinetics of doxazosin in patients with hypertension and renal impairment.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Doxazosin; Female; Glomerular Filtration Rate; Half-Life; Humans; Hypertension; Kidney Diseases; Male; Middle Aged; Prazosin; Renal Circulation | 1990 |
[Doxazosin--therapeutic advantages in hypertension].
Topics: Doxazosin; Humans; Hypertension; Prazosin | 1990 |
The mode of action of alpha 1-adrenoceptor blockers on blood lipids.
Topics: Animals; Atenolol; Cholesterol, Dietary; Cholesterol, HDL; Cricetinae; Doxazosin; Humans; Lipoprotein Lipase; Mesocricetus; Prazosin; Propranolol; Time Factors; Triglycerides | 1990 |
Doxazosin in renal impairment.
Topics: Administration, Oral; Doxazosin; Drug Administration Schedule; Glomerular Filtration Rate; Half-Life; Humans; Kidney Diseases; Prazosin; Renal Circulation | 1990 |
Pfizer introduces new antihypertensive.
Topics: Antihypertensive Agents; Doxazosin; Humans; Prazosin | 1990 |
[Doxazosin for the treatment of arterial hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Dose-Response Relationship, Drug; Doxazosin; Drug Administration Schedule; Female; Humans; Hypertension; Lipids; Male; Middle Aged; Posture; Prazosin | 1990 |
In vivo and in vitro studies of alpha 2-adrenoceptor responses in human vascular smooth muscle.
Topics: Adult; Animals; Arm; Brimonidine Tartrate; Dioxanes; Dioxins; Doxazosin; Epinephrine; Humans; Idazoxan; Male; Muscle Contraction; Muscle, Smooth, Vascular; Phenylephrine; Prazosin; Quinoxalines; Receptors, Adrenergic, alpha; Regional Blood Flow; Vasomotor System | 1985 |
Modulation of noradrenaline release by peripheral presynaptic alpha 2-adrenoceptors in humans.
Topics: Blood Pressure; Doxazosin; Heart Rate; Humans; Injections, Intra-Arterial; Male; Norepinephrine; Prazosin; Receptors, Adrenergic, alpha; Regional Blood Flow; Tyramine; Yohimbine | 1987 |
Antihypertensive effects and pharmacokinetics of single and consecutive administration of doxazosin in patients with mild to moderate essential hypertension.
Topics: Adult; Aldosterone; Blood Pressure; Catecholamines; Creatinine; Doxazosin; Electrolytes; Female; Heart Rate; Humans; Hypertension; Kinetics; Male; Middle Aged; Prazosin; Renin | 1987 |
Effects of doxazosin and propranolol administration on lipoprotein lipases in cholesterol-fed rats.
Topics: Adipose Tissue; Adrenergic alpha-Antagonists; Animals; Cholesterol, Dietary; Doxazosin; Insulin; Lipids; Lipoprotein Lipase; Liver; Male; Myocardium; Prazosin; Propranolol; Rats; Rats, Inbred Strains; Thyroid Hormones | 1987 |
Effects of doxazosin on vascular collagen synthesis, arterial pressure and serum lipids in the spontaneously hypertensive rat.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Collagen; Dose-Response Relationship, Drug; Doxazosin; Hypertension; Lipids; Male; Muscle, Smooth, Vascular; Prazosin; Rats; Rats, Inbred SHR; Time Factors | 1987 |
Effects of alpha 1-inhibition on lipid metabolism in the rat.
Topics: Adrenergic alpha-Antagonists; Animals; Cholesterol, Dietary; Dietary Carbohydrates; Doxazosin; Food Deprivation; Lipids; Male; Prazosin; Rats; Rats, Inbred Strains; Sucrose | 1987 |
Studies with doxazosin on the saturable binding of 125I-LDL by liver in normocholesterolemic mice.
Topics: Adrenergic alpha-Antagonists; Animals; Cholesterol; Dose-Response Relationship, Drug; Doxazosin; Female; Iodine Radioisotopes; Lipoproteins, LDL; Liver; Mice; Mice, Inbred Strains; Prazosin; Receptors, LDL; Triglycerides | 1987 |
Action of dopamine on isolated human saphenous veins.
Topics: Aged; Dopamine; Doxazosin; Female; Humans; In Vitro Techniques; Male; Middle Aged; Muscle, Smooth, Vascular; Norepinephrine; Prazosin; Saphenous Vein; Vasodilator Agents; Yohimbine | 1988 |
Effect of doxazosin on cholesterol synthesis in cell culture.
Topics: Adrenergic alpha-Antagonists; Animals; Cells, Cultured; Cholesterol; Cholesterol Esters; Deuterium; Doxazosin; Fibroblasts; Liver Neoplasms, Experimental; Prazosin; Receptors, LDL; Tumor Cells, Cultured | 1989 |
Mechanisms of selective alpha1-inhibition in lipid metabolism. Role of doxazosin. Proceedings of an international workshop. Puerto Rico, April 16, 1988.
Topics: Adrenergic alpha-Antagonists; Animals; Doxazosin; Humans; Lipid Metabolism; Prazosin | 1989 |
Effects of doxazosin and other antihypertensives on serum lipid levels and lipoprotein lipase in the C57BR/cdJ mouse.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Doxazosin; Lipase; Lipoprotein Lipase; Liver; Male; Mice; Mice, Inbred Strains; Prazosin; Purinones; Triglycerides | 1989 |
Interactions of doxazosin with insulin or glucagon in the ob/ob mouse.
Topics: 3-Hydroxybutyric Acid; Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Cholesterol; Doxazosin; Fatty Acids, Nonesterified; Glucagon; Glycerol; Hydroxybutyrates; Insulin; Lactates; Lactic Acid; Male; Mice; Mice, Obese; Prazosin; Triglycerides | 1989 |
Serum lipids, lipoproteins, hemodynamics, and hemostasis in doxazosin-treated monkeys.
Topics: Adrenergic alpha-Antagonists; Animals; Apolipoproteins B; Disease Models, Animal; Doxazosin; Hemodynamics; Hemostasis; Hypercholesterolemia; Lipids; Lipoproteins; Macaca fascicularis; Male; Prazosin | 1989 |
Influence of doxazosin on lipid transport in rats and hamsters.
Topics: Adrenergic alpha-Antagonists; Animals; Biological Transport; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, LDL; Cricetinae; Doxazosin; Food, Formulated; Lipid Metabolism; Liver; Male; Prazosin; Rats; Species Specificity; Triglycerides | 1989 |
Regulation of triglyceride mobilization in isolated hepatocytes by dibutyryl cyclic AMP and epinephrine.
Topics: Adrenergic alpha-Antagonists; Animals; Bucladesine; Chloroquine; Doxazosin; Epinephrine; Epoxy Compounds; Fatty Acids; Lipid Mobilization; Liver; Male; Prazosin; Propranolol; Rats; Triglycerides | 1989 |
Effect of doxazosin on plasma lipids and atherogenesis: a preliminary report.
Topics: Adrenergic alpha-Antagonists; Animals; Arteriosclerosis; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Doxazosin; Female; Foam Cells; Gerbillinae; Heart Rate; Male; Prazosin; Triglycerides | 1989 |
Effects of doxazosin on lipids, lipoprotein lipases, and cholesterol synthesis in the golden hamster.
Topics: Adrenergic alpha-Antagonists; Animals; Atenolol; Cholesterol; Cholesterol, Dietary; Cricetinae; Doxazosin; Insulin; Lipase; Lipoprotein Lipase; Liver; Male; Mesocricetus; Norepinephrine; Prazosin; Propranolol; Thyroid Hormones; Triglycerides | 1989 |
Adrenoceptors in Raynaud's disease.
Topics: Adult; Azepines; Doxazosin; Female; Fingers; Humans; Isoproterenol; Male; Middle Aged; Norepinephrine; Prazosin; Raynaud Disease; Receptors, Adrenergic; Regional Blood Flow; Skin | 1989 |
Does alpha 1-adrenergic blockade influence regional blood flow regulation in hearts with coronary artery occlusion?
Topics: Animals; Atenolol; Cats; Coronary Circulation; Coronary Disease; Doxazosin; Female; Male; Prazosin; Vasodilator Agents | 1989 |
Single-dose and steady-state pharmacokinetics of doxazosin given in combination with chlorothiazide to hypertensive subjects.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Chlorothiazide; Doxazosin; Female; Half-Life; Humans; Hypertension; Male; Middle Aged; Prazosin | 1989 |
[Marketing of Carduran].
Topics: Catalogs, Drug as Topic; Doxazosin; Humans; Prazosin | 1989 |
Delayed recovery of homogeneous perfusion distribution in isolated rat heart after vasodilatation induced by alpha 1 adrenoceptor blockade during postischaemic reperfusion.
Topics: Animals; Blood Flow Velocity; Coronary Circulation; Coronary Disease; Doxazosin; L-Lactate Dehydrogenase; Myocardial Reperfusion; Myocardium; Prazosin; Rats; Rats, Inbred Strains; Stroke Volume; Vasodilator Agents | 1989 |
Postjunctional alpha 2-adrenoceptors mediate vasoconstriction in human subcutaneous resistance vessels.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Arteries; Azepines; Brimonidine Tartrate; Doxazosin; Female; Humans; In Vitro Techniques; Male; Middle Aged; Norepinephrine; Prazosin; Quinoxalines; Receptors, Adrenergic, alpha; Regional Blood Flow; Skin; Vascular Resistance; Vasoconstriction; Veins; Yohimbine | 1989 |
Inhibition of hepatic cholesterol synthesis by the alpha 1-adrenoceptor blocker doxazosin in the hypercholesterolemic golden hamster.
Topics: Acetates; Adrenergic alpha-Antagonists; Animals; Cholesterol; Cholesterol, Dietary; Cricetinae; Doxazosin; Hypercholesterolemia; Lipoproteins; Liver; Male; Mesocricetus; Prazosin; Reference Values; Triglycerides | 1989 |
Alpha-blockade for hypertension: indifferent past, uncertain future.
Topics: Antihypertensive Agents; Coronary Disease; Doxazosin; Drug Evaluation; Humans; Hypertension; Prazosin; Prognosis | 1989 |
An in vitro study of interactions between doxazosin and enalaprilat at vascular alpha 1-adrenoceptors.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Vessels; Doxazosin; Drug Interactions; Enalapril; Enalaprilat; In Vitro Techniques; Male; Phenylephrine; Prazosin; Rats; Rats, Inbred Strains; Receptors, Adrenergic, alpha; Renin-Angiotensin System | 1989 |
Clinical settings for selective alpha-adrenergic receptor inhibition: rationale and management strategies. Proceedings of a symposium. Naples, Florida, October 13 to 16, 1988.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Doxazosin; Humans; Hypertension; Prazosin | 1989 |
Doxazosin, a new alpha-1-antagonist drug, controls hypertension without causing airways obstruction in asthma and COPD.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Asthma; Blood Pressure; Doxazosin; Female; Forced Expiratory Volume; Humans; Hypertension; Lung Diseases, Obstructive; Male; Middle Aged; Peak Expiratory Flow Rate; Prazosin; Prospective Studies; Pulmonary Ventilation; Respiration; Single-Blind Method | 1989 |
Plethysmographic effects of doxazosin in essential hypertensive patients.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Doxazosin; Drug Evaluation; Female; Humans; Hypertension; Leg; Male; Middle Aged; Plethysmography; Prazosin; Regional Blood Flow | 1989 |
Lack of differential inhibition by nifedipine of pressor responses induced by alpha 1- and alpha 2-adrenoceptor agonists and by angiotensin II in anaesthetized cats.
Topics: Adrenergic alpha-Agonists; Angiotensin II; Animals; Blood Pressure; Cats; Doxazosin; Male; Muscle, Smooth, Vascular; Nifedipine; Nordefrin; Phenylephrine; Prazosin; Vasoconstriction; Yohimbine | 1985 |
Doxazosin increases low density lipoprotein receptor activity.
Topics: Adrenergic alpha-Antagonists; Cell Line; Cells, Cultured; Child, Preschool; Doxazosin; Fibroblasts; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Prazosin; Quinazolines; Receptors, Cell Surface; Receptors, Lipoprotein | 1985 |
Pharmacokinetic and pharmacodynamic studies with two alpha-adrenoceptor antagonists, doxazosin and prazosin in the rabbit.
Topics: Adrenergic alpha-Antagonists; Angiotensin II; Animals; Antihypertensive Agents; Aorta, Thoracic; Azepines; Blood Pressure; Doxazosin; Heart Rate; Hemodynamics; Kinetics; Male; Membranes; Muscle, Smooth, Vascular; Prazosin; Rats; Time Factors | 1985 |
Alpha 1-adrenergic blockade raises epinephrine-arrhythmia threshold in halothane-anesthetized dogs in a dose-dependent fashion.
Topics: Adrenergic alpha-Antagonists; Anesthesia, Inhalation; Animals; Arrhythmias, Cardiac; Dogs; Dose-Response Relationship, Drug; Doxazosin; Droperidol; Epinephrine; Halothane; Prazosin | 1985 |
Clinical pharmacological studies with doxazosin.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aging; Antihypertensive Agents; Blood Pressure; Doxazosin; Female; Half-Life; Humans; Kinetics; Male; Prazosin | 1986 |
The alpha 1-adrenoceptor antagonist profile of doxazosin: preclinical pharmacology.
Topics: Adrenergic alpha-Antagonists; Anesthesia; Angiotensin II; Animals; Antihypertensive Agents; Cats; Dogs; Doxazosin; Electric Stimulation; Heart; Hypertension, Renal; In Vitro Techniques; Male; Muscle Contraction; Muscle, Smooth, Vascular; Nictitating Membrane; Prazosin; Rabbits; Species Specificity | 1986 |
Clinical pharmacology and therapeutic role of prazosin and related alpha-adrenoceptor antagonists.
Topics: Adrenergic alpha-Antagonists; Age Factors; Animals; Antihypertensive Agents; Blood Pressure; Doxazosin; Humans; Hypertension; Lipids; Metabolic Clearance Rate; Prazosin; Protein Binding; Receptors, Adrenergic, alpha; Renin; Structure-Activity Relationship | 1986 |
[Reduction of coronary risk factors with selective alpha-blockers. International Doxazosin Symposium. Frankfurt/Main, 7 June 1986].
Topics: Adrenergic alpha-Antagonists; Coronary Disease; Doxazosin; Humans; Prazosin; Risk | 1986 |
Effects of doxazosin on diet-induced hypercholesterolemia in C57BR/cdJ mice.
Topics: Adrenergic alpha-Antagonists; Animals; Cholesterol; Cholesterol, Dietary; Cholestyramine Resin; Disease Models, Animal; Doxazosin; Female; Hypercholesterolemia; Lipoproteins; Male; Mice; Mice, Inbred Strains; Prazosin | 1987 |
Pharmacokinetic overview of doxazosin.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Biological Availability; Biotransformation; Doxazosin; Half-Life; Humans; Injections, Intravenous; Kinetics; Middle Aged; Prazosin | 1987 |
Role of alpha 1- and alpha 2-adrenergic receptors in the human hypertensive kidney.
Topics: Adrenergic alpha-Antagonists; Adult; Doxazosin; Humans; Hypertension; Kidney; Middle Aged; Prazosin; Receptors, Adrenergic, alpha; Renal Circulation; Renin; Yohimbine | 1987 |
Pharmacokinetic and pharmacodynamic modelling of the alpha adrenoceptor antagonist doxazosin.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Biological Availability; Blood Pressure; Doxazosin; Half-Life; Humans; Injections, Intravenous; Kinetics; Male; Mathematics; Models, Biological; Prazosin | 1988 |
alpha-Adrenoceptors and cold-induced vasoconstriction in human finger skin.
Topics: Adrenergic alpha-Agonists; Azepines; Cold Temperature; Doxazosin; Fingers; Humans; Male; Phenylephrine; Prazosin; Receptors, Adrenergic, alpha; Regional Blood Flow; Skin; Vasoconstriction; Yohimbine | 1988 |
Clinical experience with doxazosin in general medical practice.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease; Doxazosin; Family Practice; Female; Heart Rate; Humans; Hypertension; Lipids; Male; Middle Aged; Prazosin | 1988 |
Doxazosin in the treatment of mild and moderate essential hypertension in general medical practice.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease; Doxazosin; Family Practice; Female; Heart Rate; Humans; Hypertension; Lipids; Male; Middle Aged; Prazosin | 1988 |
Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Coronary Disease; Doxazosin; Drug Therapy, Combination; Female; Humans; Hypertension; Lipids; Male; Middle Aged; Prazosin; Risk Factors | 1988 |
Doxazosin in the treatment of patients with mild or moderate hypertension and mild or moderate renal insufficiency.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease; Doxazosin; Female; Heart Rate; Humans; Hypertension; Kidney Diseases; Lipids; Male; Middle Aged; Prazosin | 1988 |
A single-blind study of doxazosin in the treatment of mild-to-moderate essential hypertensive patients with concomitant noninsulin-dependent diabetes mellitus.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease; Diabetes Mellitus, Type 2; Doxazosin; Female; Heart Rate; Humans; Hypertension; Lipids; Male; Middle Aged; Prazosin | 1988 |
The addition of doxazosin to the treatment regimen of hypertensive patients not responsive to nifedipine.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease; Doxazosin; Drug Resistance; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Nitrendipine; Prazosin | 1988 |
A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Coronary Disease; Doxazosin; Drug Resistance; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypertension; Lipids; Male; Middle Aged; Prazosin | 1988 |
Studies of serum lipids in hypercholesterolaemic rabbits treated with doxazosin.
Topics: Adrenergic alpha-Antagonists; Animals; Chinchilla; Cholesterol; Doxazosin; Drug Evaluation, Preclinical; Female; Hypercholesterolemia; Lipids; Prazosin | 1988 |
Doxazosin determination by high-performance liquid chromatography using fluorescence detection.
Topics: Antihypertensive Agents; Chromatography, High Pressure Liquid; Doxazosin; Humans; Prazosin; Spectrometry, Fluorescence | 1985 |
Alpha 1-adrenoreceptor blockade in hypertension: pharmacological and clinical profile of doxazosin. Proceedings of an international symposium. Venice, Italy, 14 June 1985.
Topics: Animals; Antihypertensive Agents; Doxazosin; Humans; Hypertension; Prazosin | 1986 |
The metabolism and kinetics of doxazosin in man, mouse, rat and dog.
Topics: Adult; Animals; Antihypertensive Agents; Biological Availability; Blood Proteins; Body Fluids; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Dogs; Doxazosin; Humans; Kinetics; Male; Mice; Prazosin; Protein Binding; Rats; Species Specificity | 1986 |
Acute renal effects of doxazosin in man.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Doxazosin; Humans; Kidney; Male; Middle Aged; Physical Exertion; Prazosin; Renal Circulation; Renin | 1986 |
Acute and chronic haemodynamic effects of doxazosin in hypertension at rest and during exercise.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; Doxazosin; Female; Hemodynamics; Humans; Hypertension; Injections, Intravenous; Male; Middle Aged; Physical Exertion; Prazosin; Time Factors | 1986 |
The pharmacokinetics of doxazosin in elderly normotensives.
Topics: Administration, Oral; Adult; Age Factors; Aged; Biological Availability; Blood Pressure; Doxazosin; Female; Half-Life; Humans; Injections, Intravenous; Kinetics; Male; Middle Aged; Prazosin | 1986 |
Pharmacokinetics and effect on blood pressure of doxazosin in normal subjects and patients with renal failure.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Doxazosin; Female; Humans; Kidney Failure, Chronic; Kinetics; Male; Middle Aged; Prazosin; Renal Dialysis | 1986 |
A symposium: Doxazosin: coronary artery disease risk factor management. June 7, 1986, Frankfurt, Germany.
Topics: Antihypertensive Agents; Coronary Disease; Doxazosin; Humans; Hypertension; Prazosin; Risk | 1987 |
[Doxazocin].
Topics: Animals; Antihypertensive Agents; Doxazosin; Humans; Prazosin | 1988 |
Doxazosin: A distinctive approach to risk reduction of coronary heart disease in hypertensive patients. Proceedings of a symposium. Hamburg, West Germany, January 30, 1988.
Topics: Antihypertensive Agents; Coronary Disease; Doxazosin; Humans; Hypertension; Prazosin; Risk Factors | 1988 |
Liquid chromatographic analysis of doxazosin in human serum with manual and robotic sample preparation.
Topics: Chemical Phenomena; Chemistry; Chromatography, High Pressure Liquid; Doxazosin; Humans; Prazosin; Robotics; Spectrometry, Fluorescence | 1988 |
Effect of sympathetic stimulation and intrarenal alpha-blockade on the secretion of renin by the human kidney.
Topics: Adult; Doxazosin; Female; Hemodynamics; Humans; Hypertension; Isometric Contraction; Kidney; Male; Middle Aged; Phentolamine; Prazosin; Receptors, Adrenergic, alpha; Renal Circulation; Renin; Sympathetic Nervous System | 1985 |
A comparison of the effects of doxazosin and alfuzosin with those of urapidil on preganglionic sympathetic nerve activity in anaesthetised cats.
Topics: Action Potentials; Animals; Blood Pressure; Cats; Doxazosin; Male; Piperazines; Prazosin; Quinazolines; Receptors, Adrenergic, alpha; Sympathetic Nervous System; Vascular Resistance | 1986 |
Effects of exogenous adrenaline and noradrenaline on vascular postsynaptic alpha 1- and alpha 2-adrenoceptors in man.
Topics: Adult; Blood Vessels; Dose-Response Relationship, Drug; Doxazosin; Epinephrine; Forearm; Humans; Male; Norepinephrine; Prazosin; Receptors, Adrenergic, alpha; Regional Blood Flow; Sodium Chloride; Vasoconstriction; Vasodilator Agents; Yohimbine | 1984 |
Prazosin and its analogues UK-18,596 and UK-33,274: a comparative study on cardiovascular effects and alpha-adrenoceptor blocking activities.
Topics: Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Blood Pressure; Clonidine; Doxazosin; Heart Rate; Hemodynamics; Hexobarbital; Injections, Intraventricular; Male; Phenylephrine; Prazosin; Quinazolines; Rats | 1980 |
Heterogeneity of post-junctional alpha-adrenoceptors in human vascular smooth muscle.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Dose-Response Relationship, Drug; Doxazosin; Humans; In Vitro Techniques; Muscle, Smooth, Vascular; Prazosin; Receptors, Adrenergic; Receptors, Adrenergic, alpha | 1981 |
Non-competitive antagonism of the alpha-adrenoceptor-mediated fast component of contraction of rat aorta, by doxazosin and prazosin.
Topics: Adrenergic alpha-Antagonists; Animals; Aorta; Calcium; Dose-Response Relationship, Drug; Doxazosin; In Vitro Techniques; Male; Norepinephrine; Prazosin; Quinazolines; Rats; Rats, Inbred Strains; Vasoconstriction; Vasodilator Agents | 1983 |
Analysis of the pressor dose response.
Topics: Blood Pressure; Dose-Response Relationship, Drug; Doxazosin; Drug Interactions; Epinephrine; Ethanolamines; Humans; Labetalol; Mathematics; Models, Biological; Norepinephrine; Prazosin; Pressoreceptors | 1982 |
Effects of prazosin and two of its derivatives (UK 18.596 and UK 33.274) on alpha-adrenoceptors [proceedings].
Topics: Animals; Cats; Doxazosin; Prazosin; Quinazolines; Rats; Receptors, Adrenergic; Receptors, Adrenergic, alpha | 1980 |
Identification of vascular postsynaptic alpha 1- and alpha 2-adrenoceptors in man.
Topics: Adult; Azepines; Blood Pressure; Clonidine; Dose-Response Relationship, Drug; Doxazosin; Female; Guanfacine; Guanidines; Heart Rate; Humans; Male; Methoxamine; Muscle, Smooth, Vascular; Phenylacetates; Prazosin; Receptors, Adrenergic, alpha; Receptors, Neurotransmitter; Yohimbine | 1984 |
Determination of the vasodilator UK33274 by high-performance liquid chromatography using fluorescence detection.
Topics: Chromatography, High Pressure Liquid; Doxazosin; Humans; Hypotension; Prazosin; Quinazolines; Vasodilator Agents | 1980 |
Characterization of an alpha 1D-adrenoceptor mediating the contractile response of rat aorta to noradrenaline.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Aorta; Binding, Competitive; Dose-Response Relationship, Drug; Doxazosin; Male; Norepinephrine; Piperazines; Prazosin; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-1; Vasodilation | 1995 |
Effect of alpha 1 adrenoceptor antagonists on prostatic pressure and blood pressure in the anesthetized dog.
Topics: Adrenergic alpha-Antagonists; Affinity Labels; Anesthesia, Endotracheal; Animals; Blood Pressure; Dogs; Dose-Response Relationship, Drug; Doxazosin; Male; Models, Biological; Phenylephrine; Piperazines; Prazosin; Pressure; Prostate; Quinazolines; Sulfonamides; Tamsulosin | 1994 |
A comparison of the effects of doxazosin and terazosin on the spontaneous sympathetic drive to the bladder and related organs in anaesthetized cats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Anesthesia; Animals; Blood Pressure; Cats; Doxazosin; Heart Rate; Male; Prazosin; Sympathetic Nervous System; Urinary Bladder | 1995 |
Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Aorta, Thoracic; Blood Pressure; Dogs; Dose-Response Relationship, Drug; Doxazosin; Humans; In Vitro Techniques; Male; Muscle Contraction; Muscle, Smooth, Vascular; Norepinephrine; Phenylephrine; Prazosin; Pressure; Prostate; Quinazolines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin | 1996 |
Alpha-adrenoceptor blocking drugs and female urinary incontinence: prevalence and reversibility.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Female; Humans; Prazosin; Prevalence; Urinary Incontinence | 1996 |
The alpha-adrenoceptor antagonist properties of the enantiomers of doxazosin in the human prostate.
Topics: Adrenergic alpha-Antagonists; Analysis of Variance; Binding Sites; Binding, Competitive; Cell Line; Dose-Response Relationship, Drug; Doxazosin; Humans; Male; Phenethylamines; Prazosin; Prostate; Radioligand Assay; Receptors, Adrenergic, alpha; Stereoisomerism; Tetralones | 1996 |
Pharmacological evaluation of prazosin- and doxazosin-related compounds with modified piperazine ring.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Doxazosin; In Vitro Techniques; Injections, Intraperitoneal; Intubation, Gastrointestinal; Male; Muscle Contraction; Muscle, Smooth; Prazosin; Rats; Rats, Inbred SHR | 1996 |
Effects of selective and nonselective alpha-1-adrenoceptor antagonists on intraurethral and arterial pressures in intact conscious dogs.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Dogs; Doxazosin; Male; Prazosin; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Time Factors; Urethra | 1996 |
Alpha 1-adrenergic blockers: do they have a place in the prophylaxis of migraine?
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Child; Doxazosin; Female; Humans; Male; Middle Aged; Migraine Disorders; Prazosin | 1997 |
The treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 80 years.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Doxazosin; Humans; Male; Prazosin; Prospective Studies; Prostatic Hyperplasia; Treatment Outcome; Urination | 1997 |
Alpha-adrenergic receptors regulate human lymphocyte amiloride-sensitive sodium channels.
Topics: 1-Methyl-3-isobutylxanthine; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Amiloride; Animals; Cell Transformation, Viral; Cells, Cultured; Cyclic AMP; Doxazosin; Endothelium, Vascular; Epithelial Sodium Channels; GTP-Binding Proteins; Herpesvirus 4, Human; Humans; Isoproterenol; Membrane Potentials; Norepinephrine; Patch-Clamp Techniques; Prazosin; Rats; Receptors, Adrenergic, alpha; Recombinant Proteins; Second Messenger Systems; Sodium Channels; Thionucleotides; Transcription, Genetic | 1998 |
Comparison of relaxation responses of cavernous and trigonal smooth muscles from rabbits by alpha1-adrenoceptor antagonists; prazosin, terazosin, doxazosin, and tamsulosin.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Doxazosin; In Vitro Techniques; Muscle Contraction; Muscle Relaxation; Muscle, Smooth; Prazosin; Rabbits; Sulfonamides; Tamsulosin | 1999 |
Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Apoptosis; Cell Division; Doxazosin; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Retrospective Studies | 1999 |
Doxazosin-to-terazosin switch for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Doxazosin; Drug Prescriptions; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; United States; United States Department of Veterans Affairs | 1999 |
Characterization of human recombinant alpha(2A)-adrenoceptors expressed in Chinese hamster lung cells using extracellular acidification rate changes.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Azepines; Brimonidine Tartrate; Cell Line; Cricetinae; Dexmedetomidine; Dose-Response Relationship, Drug; Doxazosin; Gene Expression; Humans; Hydrogen-Ion Concentration; Imidazoles; Norepinephrine; Prazosin; Quinoxalines; Receptors, Adrenergic, alpha-2; Recombinant Fusion Proteins; Tetrahydronaphthalenes; Yohimbine | 2000 |
Characterization of human recombinant alpha(2A)-adrenoceptors expressed in Chinese hamster lung cells using intracellular Ca(2+) changes: evidence for cross-talk between recombinant alpha(2A)- and native alpha(1)-adrenoceptors.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Aniline Compounds; Animals; Azepines; Binding, Competitive; Brimonidine Tartrate; Calcium; Cell Line; Cricetinae; Dexmedetomidine; Dose-Response Relationship, Drug; Doxazosin; Estrenes; Fluorescence; Gene Expression; Humans; Imidazoles; Norepinephrine; Prazosin; Pyrrolidinones; Quinoxalines; Radioligand Assay; Receptor Cross-Talk; Receptors, Adrenergic, alpha-1; Receptors, Adrenergic, alpha-2; Recombinant Fusion Proteins; Signal Transduction; Tetrahydronaphthalenes; Thapsigargin; Xanthenes; Yohimbine | 2000 |
Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Antagonists; Animals; Antineoplastic Agents; Apoptosis; Cell Division; Cells, Cultured; Doxazosin; Growth Inhibitors; Humans; Male; Mice; Mice, SCID; Muscle, Smooth; Neoplasm Transplantation; Prazosin; Prostate; Prostatic Neoplasms; Receptors, Adrenergic, alpha-1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Tamsulosin; Transplantation, Heterologous | 2000 |
Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Biopsy; Cell Division; Doxazosin; Humans; Male; Muscle, Smooth; Prazosin; Prostate; Prostatic Diseases; Prostatic Hyperplasia; Prostatic Neoplasms; Stromal Cells; Sulfonamides; Tamsulosin | 2000 |
Transurethral resection of the prostate: failure patterns and surgical outcomes in patients with symptoms refractory to alpha-antagonists.
Topics: Adrenergic alpha-Antagonists; Aged; Comorbidity; Doxazosin; Humans; Louisiana; Male; Postoperative Complications; Prazosin; Prostatic Hyperplasia; Retrospective Studies; Risk Factors; Statistics, Nonparametric; Transurethral Resection of Prostate; Treatment Failure; Treatment Outcome; Urologic Diseases | 2000 |
A quantitative analysis of antagonism and inverse agonism at wild-type and constitutively active hamster alpha1B-adrenoceptors.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Cell Line; Chromones; Cricetinae; Dose-Response Relationship, Drug; Doxazosin; Fibroblasts; Inositol Phosphates; Phenethylamines; Prazosin; Quinazolines; Rats; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin; Tetralones; Tritium | 2001 |
Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Cell Line; Dogs; Doxazosin; Drug Design; Humans; Indicators and Reagents; Indoles; Isoindoles; L Cells; Male; Mice; Models, Molecular; Molecular Conformation; Prazosin; Prostate; Prostatic Hyperplasia; Quinazolines; Radioligand Assay; Rats; Receptors, Adrenergic, alpha-1; Recombinant Proteins; Spleen; Structure-Activity Relationship; Vas Deferens | 2001 |
Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study.
Topics: Accidental Falls; Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Cohort Studies; Comorbidity; Diabetes Mellitus; Diarrhea; Dizziness; Doxazosin; Drug Therapy, Combination; Fractures, Bone; Heart Diseases; Humans; Hypertension; Hypotension; Male; Neoplasms; Prazosin; Prostatic Hyperplasia; Retrospective Studies; Stroke; Syncope | 2001 |
Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Dose-Response Relationship, Drug; Doxazosin; Humans; Male; Prazosin; Prostatic Neoplasms; Quinazolines; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin; Tumor Cells, Cultured | 2002 |
Apoptotic and proliferative index after Alpha-1-adrenoceptor antagonist and/or finasteride treatment in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Retrospective Studies | 2002 |
Doxazosin induces apoptosis in cardiomyocytes cultured in vitro by a mechanism that is independent of alpha1-adrenergic blockade.
Topics: 3T3 Cells; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Apoptosis; Calcineurin Inhibitors; Cell Survival; Cells, Cultured; Doxazosin; Heart; Humans; Mice; Myocardium; Piperazines; Prazosin; Rats; Rats, Sprague-Dawley | 2003 |
Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Anoikis; Cell Adhesion; Cell Survival; Doxazosin; Endothelial Growth Factors; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Intercellular Signaling Peptides and Proteins; Lymphokines; Male; Neoplasm Invasiveness; Prazosin; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Tamsulosin; Transcription Factors; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
[Chiral separation and preparation of three new antagonists of alpha 1-adrenoceptors by chiral mobile phase HPLC].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Chromatography, High Pressure Liquid; Doxazosin; Molecular Structure; Prazosin; Quinazolines | 2002 |
Validated specific HPLC methods for determination of prazosin, terazosin and doxazosin in the presence of degradation products formed under ICH-recommended stress conditions.
Topics: Chromatography, High Pressure Liquid; Doxazosin; Prazosin; Reproducibility of Results; Stress, Mechanical | 2004 |
Herbal and vitamin supplement use in a prostate cancer screening population.
Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Adult; Aged; Colorado; Complementary Therapies; Dietary Supplements; Doxazosin; Drug Utilization; Family; Finasteride; Health Surveys; Humans; Male; Mass Screening; Middle Aged; Penile Erection; Phytotherapy; Plant Preparations; Prazosin; Prostatic Hyperplasia; Prostatic Neoplasms; Self Medication; Socioeconomic Factors; Sulfonamides; Surveys and Questionnaires; Tamsulosin; Urination Disorders; Vitamins | 2004 |
A current review of medical therapy for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Algorithms; Azasteroids; Cholestenone 5 alpha-Reductase; Doxazosin; Drug Therapy, Combination; Dutasteride; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Urination Disorders | 2004 |
Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin.
Topics: Adrenergic alpha-Antagonists; Animals; Apoptosis; Cells, Cultured; Doxazosin; Electric Stimulation; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Patch-Clamp Techniques; Potassium Channels, Voltage-Gated; Prazosin; Xenopus | 2004 |
A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus; Doxazosin; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Probability; Prostatic Hyperplasia; Quinazolines; Reference Values; Retrospective Studies; Risk Assessment; Severity of Illness Index; Sulfonamides; Tamsulosin; Treatment Outcome; Urination Disorders; Urodynamics | 2004 |
Alpha1-adrenergic antagonists and floppy iris syndrome: tip of the iceberg?
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Doxazosin; Humans; Intraoperative Complications; Iris Diseases; Phacoemulsification; Prazosin; Pupil; Quinazolines; Sulfonamides; Syndrome; Tamsulosin | 2005 |
In vivo studies on the effects of alpha1-adrenoceptor antagonists on pupil diameter and urethral tone in rabbits.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Dose-Response Relationship, Drug; Doxazosin; Male; Prazosin; Pupil; Quinazolines; Rabbits; Receptors, Adrenergic, alpha-1; Time Factors; Urethra | 2006 |
alpha-blocker treatment of urolithiasis.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Drug Therapy, Combination; Glucocorticoids; Humans; Prazosin; Sulfonamides; Tamsulosin; Urolithiasis | 2006 |
The effects of systemic alpha-1 adrenergic antagonists on pupil diameter in rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Doxazosin; Iris; Male; Prazosin; Pupil; Rats; Rats, Sprague-Dawley; Sulfonamides; Tamsulosin | 2007 |
Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Antineoplastic Agents; Doxazosin; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Prazosin; Proportional Hazards Models; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome; United States | 2007 |
Human epididymal and prostatic tracts of vas deferens: different contraction response to noradrenaline stimulation in isolated organ bath assay.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Agonists; Aged; Dose-Response Relationship, Drug; Doxazosin; Epididymis; Humans; In Vitro Techniques; Male; Middle Aged; Muscle Contraction; Muscle, Smooth; Norepinephrine; Organ Specificity; Prazosin; Prostate; Quinazolines; Stimulation, Chemical; Vas Deferens | 2007 |
alpha(1)-Adrenoceptor antagonists prevent paracetamol-induced hepatotoxicity in mice.
Topics: Acetaminophen; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Catecholamines; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Doxazosin; Erythrocytes; Gene Expression Regulation, Enzymologic; Glutamate-Cysteine Ligase; Glutathione; Heme Oxygenase-1; Liver; Liver Circulation; Liver Diseases; Male; Membrane Proteins; Mice; Prazosin; Protein Binding; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin; Time Factors; Transaminases | 2008 |
Intraoperative floppy-iris syndrome associated with systemic alpha blockers.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Cataract Extraction; Doxazosin; Humans; Intraoperative Complications; Iris Diseases; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Syndrome; Tamsulosin | 2008 |
Effects of four different alpha(1)-adrenoceptor antagonists on alpha-adrenoceptor agonist-induced contractions in isolated mouse and hamster ureters.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Cricetinae; Doxazosin; Indoles; Male; Mesocricetus; Mice; Mice, Inbred ICR; Muscle Contraction; Norepinephrine; Prazosin; Quinazolines; Ureter | 2009 |
Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport.
Topics: Adrenergic alpha-Antagonists; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Daunorubicin; Digoxin; Doxazosin; Drug Resistance, Multiple; HeLa Cells; Humans; Neoplasm Proteins; Prazosin; Vinblastine | 2009 |
Pheochromocytoma in children and adolescents.
Topics: Adolescent; Adrenal Gland Neoplasms; Adrenalectomy; Adrenergic alpha-Antagonists; Child; Doxazosin; Female; Humans; Hypertension; Intraoperative Complications; Male; Pheochromocytoma; Prazosin; Treatment Outcome | 2009 |
Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Azasteroids; Capsules; Cholestenone 5 alpha-Reductase; Chromatography, High Pressure Liquid; Doxazosin; Drug Contamination; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Phytotherapy; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tablets; Tamsulosin | 2010 |
Enantioselective determination of doxazosin in human plasma by liquid chromatography-tandem mass spectrometry using ovomucoid chiral stationary phase.
Topics: Adrenergic alpha-1 Receptor Antagonists; Chromatography, Liquid; Doxazosin; Drug Stability; Humans; Least-Squares Analysis; Ovomucin; Prazosin; Reproducibility of Results; Sensitivity and Specificity; Stereoisomerism; Tandem Mass Spectrometry | 2010 |
Comparison of effects of alpha receptor blockers on endothelial functions and coagulation parameters in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Coagulation; Blood Pressure; Brachial Artery; Doxazosin; Endothelial Cells; Endothelium, Vascular; Humans; Male; Middle Aged; Prazosin; Prostate-Specific Antigen; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Ultrasonography | 2011 |
Cell membrane chromatography competitive binding analysis for characterization of α1A adrenoreceptor binding interactions.
Topics: Adrenergic alpha-1 Receptor Antagonists; Binding, Competitive; Cell Line; Cell Membrane; Chromatography; Doxazosin; Humans; Methods; Phentolamine; Piperazines; Prazosin; Protein Binding; Quinazolines; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin | 2011 |
Pharmacologic pupil dilation as a predictive test for the risk for intraoperative floppy-iris syndrome.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Cohort Studies; Doxazosin; Drug Combinations; Humans; Intraoperative Complications; Iris Diseases; Male; Muscle, Smooth; Mydriatics; Phacoemulsification; Phenylephrine; Prazosin; Predictive Value of Tests; Prospective Studies; Pupil; Risk Factors; Sensitivity and Specificity; Sulfonamides; Syndrome; Tamsulosin; Tropicamide | 2011 |
Revelation on the potency of α(1) -blockers - parallel blockade of angiotensin II receptor: a new finding.
Topics: Adrenergic alpha-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta, Thoracic; Dose-Response Relationship, Drug; Doxazosin; Imidazoles; In Vitro Techniques; Losartan; Male; Molecular Structure; Prazosin; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptors, Adrenergic, alpha-1; Structure-Activity Relationship; Tetrazoles; Valine; Valsartan; Vasodilation; Vasodilator Agents | 2012 |
Prescriber monitoring for benign prostatic hyperplasia within a family medicine clinic: a comparison of medication classes.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Doxazosin; Drug Therapy, Combination; Family Practice; Humans; Indoles; Male; Middle Aged; Practice Patterns, Physicians'; Prazosin; Prostatic Hyperplasia; Quinazolines; Retrospective Studies; Sulfonamides; Tamsulosin | 2012 |
Rapid and sensitive online determination of some selective α1-blockers by flow injection analysis with micelle-enhanced fluorescence detection.
Topics: Adrenergic alpha-1 Receptor Antagonists; Doxazosin; Flow Injection Analysis; Fluorescence; Internet; Micelles; Prazosin; Quinazolines; Spectrometry, Fluorescence; Time Factors | 2013 |
Rayleigh light scattering detection of three α1-adrenoceptor antagonists coupled with high performance liquid chromatograph.
Topics: Adrenergic alpha-Antagonists; Chromatography, High Pressure Liquid; Dimerization; Doxazosin; Dynamic Light Scattering; Humans; Hydrogen Bonding; Limit of Detection; Models, Molecular; Prazosin | 2015 |
Alpha blocker monotherapy versus combination therapy with antimuscarinics in men with persistent LUTS refractory to alpha-adrenergic treatment: patterns of persistence.
Topics: Administrative Claims, Healthcare; Adrenergic alpha-Antagonists; Aged; Benzofurans; Doxazosin; Drug Therapy, Combination; Humans; Longitudinal Studies; Male; Mandelic Acids; Medication Adherence; Middle Aged; Muscarinic Antagonists; Ontario; Prazosin; Prostatic Hyperplasia; Prostatism; Pyrrolidines; Quinazolines; Retrospective Studies; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tolterodine Tartrate | 2015 |
Relative cytotoxic potencies and cell death mechanisms of α1 -adrenoceptor antagonists in prostate cancer cell lines.
Topics: Adrenergic alpha-1 Receptor Antagonists; Antineoplastic Agents; Apoptosis; Autophagy; Cell Death; Cell Line, Tumor; Cell Survival; Doxazosin; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Male; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Prazosin; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sulfonamides; Tamsulosin | 2016 |
Effects of prazosin and doxazosin on yohimbine-induced reinstatement of alcohol seeking in rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Alcohol Drinking; Animals; Brain Chemistry; Doxazosin; Extinction, Psychological; Genes, fos; Injections, Intraventricular; Male; Prazosin; Rats; Rats, Long-Evans; Rats, Sprague-Dawley; Self Administration; Yohimbine | 2016 |
An efficient spectrofluorimetric method adopts doxazosin, terazosin and alfuzosin coupling with orthophthalaldehyde: Application in human plasma.
Topics: Doxazosin; Fluorescence; Humans; Limit of Detection; o-Phthalaldehyde; Plasma; Prazosin; Quinazolines; Spectrometry, Fluorescence | 2018 |
[Quantification of (-)doxazosin at very low concentration in rat plasma samples by SPE-LC-MS/MS].
Topics: Administration, Intravenous; Animals; Chromatography, Liquid; Doxazosin; Plasma; Prazosin; Rats; Sensitivity and Specificity; Solid Phase Extraction; Stereoisomerism; Tandem Mass Spectrometry | 2016 |
Micellar enhanced spectrofluorimetric approach for nanogram detection of certain α
Topics: Adrenergic alpha-1 Receptor Antagonists; Antihypertensive Agents; Doxazosin; Fluorescence; Humans; Limit of Detection; Micelles; Pharmaceutical Preparations; Plasma; Prazosin; Quinazolines; Spectrometry, Fluorescence; Tablets | 2018 |
Evaluation of syncope association with α
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Doxazosin; Humans; Hypertension; Indoles; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Quinazolines; Syncope; Tamsulosin | 2019 |
Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Cohort Studies; Databases, Factual; Denmark; Doxazosin; Female; Follow-Up Studies; Glycolysis; Humans; Male; Middle Aged; Parkinson Disease; Prazosin; Quinazolines; Registries; Risk Factors; Tamsulosin; United States | 2021 |
A Concise and Useful Guide to Understand How Alpha
Topics: Adrenergic alpha-Antagonists; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Doxazosin; Epinephrine; Norepinephrine; Prazosin; Receptors, Adrenergic, alpha-1 | 2022 |
6-nitrodopamine is a major endogenous modulator of human vas deferens contractility.
Topics: Adrenergic Antagonists; Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Carbamazepine; Chromatography, Liquid; Desipramine; Dopamine; Doxazosin; Epinephrine; Humans; Male; Muscle Contraction; Muscle, Smooth; NG-Nitroarginine Methyl Ester; Nitric Oxide; Norepinephrine; Prazosin; Rats; Receptors, Adrenergic; Tamsulosin; Tandem Mass Spectrometry; Vas Deferens | 2022 |
Adverse events related to alpha-blockers: analysis of real-life data from Eudra-Vigilance.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Hypotension, Orthostatic; Prazosin; Tamsulosin; Urogenital Diseases | 2023 |